in vitro毒性試験市場規模、シェア、動向、2031年までの世界予測

in vitro毒性試験市場は、2026年の推定126億9,000万米ドルから、2031年には209億7,000万米ドルに成長し、予測期間中の年平均成長率（CAGR）は10.6%に達するとMarketsandMarketsでは予測しています。

この成長を牽引しているのは、細胞ベースアッセイ、3D培養モデル、オルガノイド、オルガンオンチップシステム、ハイスループットスクリーニング、自動化、そして初期段階の化合物スクリーニングと安全性プロファイリングのためのAIを活用した予測毒性試験の利用拡大です。さらに、医薬品およびバイオテクノロジー分野の研究開発費の増加、より迅速かつヒトに関連性​​の高い毒性予測への需要の高まり、CROへのアウトソーシング、そして動物実験の削減と前臨床意思決定の改善を目指す規制の動きも、市場の成長を後押ししています。

調査範囲：

本調査レポートは、in vitro毒性試験（インビトロ毒性試験）市場を以下のカテゴリーに分類しています。{製品［試薬・消耗品（細胞株・初代細胞、培養試薬、培地・消耗品、3Dモデル・組織システム、その他の試薬・消耗品）、アッセイキット（細胞毒性試験、遺伝毒性試験、臓器特異的毒性試験、その他の試験）、機器（検出・画像処理・分析システム（画像処理システム、検出機器、その他の機器）、液体処理・自動化システム、その他の機器）、ソフトウェア・情報システム、サービス］；製品－毒性エンドポイント別（臓器毒性試験、細胞毒性試験、遺伝毒性試験、皮膚毒性・皮膚刺激性、腐食・感作性、酸化ストレス・メカニズム毒性、その他の毒性エンドポイント・試験）製品 – 技術別 (細胞培養技術、ハイスループットおよびハイコンテンツ技術、オミクス技術、器官型および微小生理学的技術、その他の技術)；製品 – 方法別 (細胞ベースの毒性試験方法、生化学的毒性試験方法、インシリコ/計算毒性試験方法、エクスビボモデルベースの毒性試験方法、分子およびオミクスベースの毒性試験方法、その他の方法)；製品 – エンドユーザー別 (製薬およびバイオテクノロジー企業、消費者ケア企業、食品および飲料企業、Cros、学術および研究機関、その他のエンドユーザー)；サービス – タイプ別 (毒性試験サービス、生物学的モデルおよびアッセイ開発サービス、イメージングおよび分析毒性サービス、データ分析、バイオインフォマティクス、および予測毒性学)；サービス – 方法別（細胞ベース毒性試験法、生化学毒性試験法、インシリコ／計算毒性試験法、エクスビボモデルベース毒性試験法、分子・オミクスベース毒性試験法、その他の方法）；サービス – エンドユーザー別（製薬・バイオテクノロジー企業、消費者向け製品企業、食品・飲料企業、学術・研究機関、その他のエンドユーザー）。

本レポートは、in vitro毒性試験（インビトロ毒性試験）市場の成長を左右する主要な要因（推進要因、トレンド、課題、機会など）に関する詳細な情報を網羅しています。主要企業について包括的な分析を行い、事業概要、製品、主要戦略、提携、パートナーシップ、契約に関する洞察を提供します。また、in vitro毒性試験市場における新製品発売、合併・買収などの最新動向についても取り上げています。

本レポートを購入する主なメリット：

本レポートは、市場リーダーや新規参入企業に対し、体外毒性試験市場全体およびそのサブセグメントの収益に関する最も正確な概算値を提供することで、市場戦略の策定を支援します。また、関係者が競争環境をより深く理解し、事業のポジショニングを改善し、適切な市場参入戦略を策定するための洞察を得るのに役立ちます。さらに、本レポートは、市場の動向を把握し、主要な市場推進要因、阻害要因、機会、課題に関する情報を提供することで、関係者の意思決定を支援します。

本レポートは、以下のポイントに関する洞察を提供します。

市場の成長に影響を与える主要な推進要因（非動物毒性試験法への業界全体のシフト、技術革新の進展）、阻害要因（複雑なエンドポイントにおけるin vivoとin vitroの相関性の限界）、機会（AI/MLを活用した予測毒性試験、in vitro法を用いた創薬への注目の高まり、大麻、電子タバコ、新規製品の安全性試験）、および課題（AI駆動型毒性試験における倫理的・規制上の課題）の分析

• 製品/サービス開発/イノベーション：in vitro毒性試験（インビトロ毒性試験）市場における新製品/サービスの詳細な分析
• 市場開発：様々な地域における有望な市場に関する包括的な情報
• 市場の多様化：in vitro毒性試験（体外毒性試験）市場における新製品、未開拓地域、最近の動向、および投資に関する包括的な情報
• 競合評価：Thermo Fisher Scientific Inc.（米国）、Merck KGaA（ドイツ）、Eurofins Scientific（ルクセンブルク）、Laboratory Corporationアメリカ・ホールディングス（米国）、チャールズ・リバー・ラボラトリーズ（米国）、SGS SA（スイス）、バイオ・ラッド・ラボラトリーズ（米国）、エボテックSE（ドイツ）、プロメガ・コーポレーション（米国）、カタレント（米国）、アジレント・テクノロジー（米国）、インターテック・グループ（英国）、レヴィティ（米国）、イノティブ（米国）、バイオIVT（米国）、ロンザ（スイス）、クリエイティブ・バイオラボ（米国）、上海メディシロン（中国）、クリエイティブ・バイオアレイ（米国）、アラゲン・ライフ・サイエンス（インド）、エンゾ・バイオケム（米国）、マイクロバック・ラボラトリーズ（米国）、ヴィムタ・ラボ（インド）、パシフィック・バイオラボ（米国）、MBリサーチ・ラボラトリーズ（米国）などが市場に参入している。

Report Description

The in vitro toxicology testing market is projected to reach USD 20.97 billion by 2031, growing from an estimated USD 12.69 billion in 2026, at a CAGR of 10.6% during the forecast period. Growth is being driven by increasing use of cell-based assays, 3D culture models, organoids, organ-on-chip systems, high-content screening, automation, and AI-enabled predictive toxicology for early-stage compound screening and safety profiling. The market is further supported by rising pharmaceutical and biotechnology R&D spending, demand for faster and more human-relevant toxicity prediction, outsourcing to CROs, and regulatory momentum to reduce animal testing while improving preclinical decision-making.

“The products segment accounted for a larger share than the services segment in 2025.”

By offering,  the products segment accounted for the largest share in the global in vitro toxicology testing market. The products segment led the market because in vitro toxicology workflows depend heavily on recurring product consumption, including assay kits, reagents, cell culture media, sera, buffers, microplates, detection substrates, reference standards, and validated cell models. Unlike services, these products are repeatedly required across every cytotoxicity, genotoxicity, organ toxicity, dermal, ocular, and mechanistic toxicity study.

“North America dominated the in vitro toxicology testing market in 2025.”

North America dominated the in vitro toxicology testing market in 2025, primarily due to the strong presence of pharmaceutical and biotechnology companies, advanced CRO infrastructure, well-funded academic research centers, and early adoption of non-animal safety testing technologies across the US and Canada. The region has high demand for cytotoxicity, genotoxicity, hepatotoxicity, cardiotoxicity, and mechanistic toxicity testing during drug discovery, preclinical development, cosmetics safety assessment, chemical evaluation, and medical device biocompatibility testing. The US also has a mature ecosystem of assay kit suppliers, cell model providers, organ-on-chip companies, high-content screening platforms, and predictive toxicology software developers, supporting broad commercialization of in vitro toxicology products and services. Regulatory modernization initiatives encouraging alternative methods to animal testing further support adoption.

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side – 70%; Demand Side 30%
• By Designation: Managers – 45%; CXO & Directors – 30%; and Executives – 25%
• By Region: North America – 40%; Europe – 25%; Asia Pacific – 20%; Latin America – 10%; and Middle East & Africa – 5%

List of Companies Profiled in the Report:

• Thermo Fisher Scientific Inc. (US)
• Merck KGaA (Germany)
• Eurofins Scientific (Luxembourg)
• Laboratory Corporation of America Holdings (US)
• Charles River Laboratories (US)
• SGS SA (Switzerland)
• Bio-Rad Laboratories, Inc. (US)
• Evotec SE (Germany)
• Promega Corporation (US)
• Catalent, Inc. (US)
• Agilent Technologies, Inc. (US)
• Intertek Group plc (UK)
• Revvity (US)
• Inotiv (US)
• BioIVT (US)
• Lonza (Switzerland)
• Creative Biolabs (US)
• Shanghai Medicilon Inc. (China)
• Creative Bioarray (US)
• Aragen Life Sciences Ltd. (India)
• Enzo Biochem Inc. (US)
• Microbac Laboratories, Inc. (US)
• Vimta Labs Ltd. (India)
• Pacific BioLabs Inc. (US)
• MB Research Laboratories (US)

Research Coverage:

This research report categorizes the in vitro toxicology testing market by offering {Products [Reagents & Consumables (Cell Lines & Primary Cells, Culture Reagents, Media & Consumables, 3D Models and Tissue Systems, Other Reagents & Consumables), Assay Kits (Cytotoxicity Assay, Genotoxicity Assay, Organ-Specific Toxicity Assay, Other Assays), Equipment (Detection, Imaging & Analytical Systems (Imaging Systems, Detection Instruments, Other Instruments), Liquid Handling & Automation Systems, Other Equipment), Software & Informatics, and Services; Product – By Toxicity End Point (Organ Toxicity Testing, Cytotoxicity Testing, Genotoxicity Testing, Dermal Toxicity and Skin Irritation, Corrosion and Sensitization, Oxidative Stress and Mechanistic Toxicity, Other Toxicity Endpoints and Tests); Product – By Technology (Cell Culture Technologies, High-Throughput and High-Content Technologies, Omics Technologies, Organotypic and Microphysiological Based Technologies, Other Technologies); Product – By Method (Cell-Based Toxicity Testing Method, Biochemical Toxicity Testing Method, In Silico/Computational Toxicity Testing Method, Ex Vivo Models-Based Toxicity Testing Method, Molecular & Omics-Based Toxicology Method, Other Methods); Product – By End User (Pharmaceuticals & Biotechnology Companies, Consumer Care Companies, Food & Beverages Companies, Cros, Academic And Research Institutes, Other End Users); Service- By Type (Toxicology Testing Service, Biological Model And Assay Development Services, Imaging And Analytical Toxicology Services, Data Analysis, Bioinformatics, And Predictive Toxicology); Service – By Method (Cell-Based Toxicity Testing Method, Biochemical Toxicity Testing Method, In Silico/Computational Toxicity Testing Method, Ex Vivo Models-Based Toxicity Testing Method, Molecular & Omics-Based Toxicology Method, Other Methods); Service – By End User (Pharmaceuticals & Biotechnology Companies, Consumer Care Companies, Food & Beverages Companies, Academic And Research Institutes, Other End Users).

The report’s scope encompasses detailed information regarding major influencing factors such as drivers, trends, challenges, and opportunities shaping the growth of the in vitro toxicology testing market. A comprehensive analysis of key industry players has been conducted to offer insights into their business overview, products, key strategies, collaborations, partnerships, and agreements. The report also covers recent developments, including new product launches, mergers, and acquisitions, in the in vitro toxicology testing market.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall in vitro toxicology testing market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights into the following pointers:

• Analysis of key drivers (Growing industry shift toward non-animal toxicology testing methods, increasing technological advancements), restraints (Limited in vivo-to-in vitro correlation for complex endpoints), opportunities (AI/ML-powered predictive toxicology, increasing focus on drug discovery using in vitro methods, cannabis, e-cigarette, and novel product safety testing), and challenges (Ethical and regulatory challenges in AI-driven toxicology), influencing the growth of the market
• Product/Service Development/Innovation: Detailed insights on newly launched products/services of the in vitro toxicology testing market
• Market Development: Comprehensive information about lucrative markets across varied regions
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the in vitro toxicology testing market
• Competitive Assessment: Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Eurofins Scientific (Luxembourg), Laboratory Corporation of America Holdings (US), Charles River Laboratories (US), SGS SA (Switzerland), Bio-Rad Laboratories, Inc. (US), Evotec SE (Germany), Promega Corporation (US), Catalent, Inc. (US), Agilent Technologies, Inc. (US), Intertek Group plc (UK), Revvity (US), Inotiv (US), BioIVT (US), Lonza (Switzerland), Creative Biolabs (US), Shanghai Medicilon Inc. (China), Creative Bioarray (US), Aragen Life Sciences Ltd. (India), Enzo Biochem Inc. (US), Microbac Laboratories, Inc. (US), Vimta Labs Ltd. (India), Pacific BioLabs Inc. (US), and MB Research Laboratories (US), among others, in the market

Table of Contents

1 INTRODUCTION 60
1.1 STUDY OBJECTIVES 60
1.2 MARKET DEFINITION 60
1.3 MARKET SCOPE 61
1.3.1 MARKETS COVERED 61
1.3.2 INCLUSIONS & EXCLUSIONS 62
1.3.3 YEARS CONSIDERED 63
1.3.4 CURRENCY CONSIDERED 63
1.4 STAKEHOLDERS 63
2 EXECUTIVE SUMMARY 64
2.1 KEY INSIGHTS AND MARKET HIGHLIGHTS 64
2.2 KEY MARKET PARTICIPANTS: SHARE INSIGHTS AND STRATEGIC DEVELOPMENTS 65
2.3 DISRUPTIVE TRENDS SHAPING THE MARKET 66
2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS 67
2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST 68
3 PREMIUM INSIGHTS 69
3.1 IN VITRO TOXICOLOGY TESTING MARKET OVERVIEW 69
3.2 NORTH AMERICA: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY TYPE 70
3.3 IN VITRO TOXICOLOGY TESTING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 71
3.4 IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET SHARE, BY END USER, 2026 VS 2031 (%) 71
4 MARKET OVERVIEW 72
4.1 INTRODUCTION 72
4.2 MARKET DYNAMICS 72
4.2.1 DRIVERS 74
4.2.1.1 Growing Industry Shift Toward Non-Animal Toxicology Testing Methods 74
4.2.1.2 Increasing Technological Advancements 74
4.2.1.3 Rising Pharmaceutical R&D Expenditure and Drug Attrition Costs 74
4.2.2 RESTRAINTS 75
4.2.2.1 Limited In Vivo-to-In Vitro Correlation for Complex Endpoints 75
4.2.2.2 High Cost of Advanced Platforms (Organ-on-Chip, 3D Models) 75
4.2.3 OPPORTUNITIES 75
4.2.3.1 AI/ML-Powered Predictive Toxicology 75
4.2.3.2 Increasing Focus on Drug Discovery Using In Vitro Methods 76
4.2.3.3 Cannabis, E-Cigarette, and Novel Product Safety Testing 76
4.2.4 CHALLENGES 76
4.2.4.1 Ethical and Regulatory Challenges in AI-Driven Toxicology 76
4.3 UNMET NEEDS AND WHITE SPACES 77
4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES 77
4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS 77
5 INDUSTRY TRENDS 79
5.1 PORTER’S FIVE FORCES ANALYSIS 79
5.1.1 THREAT OF NEW ENTRANTS 80
5.1.2 THREAT OF SUBSTITUTES 80
5.1.3 BARGAINING POWER OF BUYERS 80
5.1.4 BARGAINING POWER OF SUPPLIERS 80
5.1.5 INTENSITY OF COMPETITIVE RIVALRY 80
5.2 MACROECONOMIC OUTLOOK 81
5.2.1 INTRODUCTION 81
5.2.2 GDP TRENDS AND FORECAST 81
5.2.3 TRENDS IN GLOBAL IN VITRO TOXICOLOGY TESTING MARKET 81
5.3 VALUE CHAIN ANALYSIS 82
5.4 ECOSYSTEM ANALYSIS 83
5.5 PRICING ANALYSIS 85
5.5.1 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY PRODUCT, 2025 86
5.5.2 INDICATIVE SELLING PRICE, BY REGION, 2025 86
5.6 KEY CONFERENCES & EVENTS 87
5.7 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 87
5.8 INVESTMENT/FUNDING ACTIVITY 88
5.9 IMPACT OF 2025 TARIFFS—IN VITRO TOXICOLOGY TESTING MARKET 89
5.9.1 INTRODUCTION 89
5.9.2 KEY TARIFF RATES 89
5.9.3 PRICE IMPACT ANALYSIS 90
5.9.4 IMPACT ON COUNTRIES/REGIONS 90
5.9.4.1 North America 90
5.9.4.2 Europe 91
5.9.4.3 Asia Pacific 91
5.9.5 IMPACT ON END-USE INDUSTRIES 91
5.9.5.1 Pharmaceutical and biotechnology companies 92
5.9.5.2 CROs 92
5.9.5.3 Academic & Research Institutes 92
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS 93
6.1 KEY TECHNOLOGIES 93
6.1.1 CELL CULTURE TECHNOLOGIES 93
6.1.2 OMICS TECHNOLOGIES 93
6.2 ADJACENT TECHNOLOGIES 94
6.2.1 COMPUTATIONAL TOXICOLOGY AND AI 94
6.3 COMPLEMENTARY TECHNOLOGIES 94
6.3.1 LAB-ON-A-CHIP (LOC)/ORGAN-ON-A-CHIP (OOC) SYSTEMS 94
6.4 TECHNOLOGY/PRODUCT ROADMAP 95
6.5 PATENT ANALYSIS 95
6.5.1 TOP APPLICANTS/OWNERS (COMPANIES) FOR IN VITRO TOXICOLOGY TESTING PATENTS, 2015–2025 96
6.6 FUTURE APPLICATIONS 97
6.7 IMPACT OF AI/GEN AI ON IN VITRO TOXICOLOGY TESTING MARKET 97
6.7.1 TOP USE CASES AND MARKET POTENTIAL 98
6.7.2 CASE STUDIES OF AI IMPLEMENTATION IN IN VITRO TOXICOLOGY TESTING MARKET 99
6.7.3 INTERCONNECTED ADJACENT ECOSYSTEM AND IMPACT ON MARKET PLAYERS 99
6.7.4 CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN IN VITRO TOXICOLOGY TESTING MARKET 99
7 SUSTAINABILITY AND REGULATORY LANDSCAPE 102
7.1 REGIONAL REGULATIONS AND COMPLIANCE 102
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 102
7.1.2 REGULATORY FRAMEWORK 105
7.1.3 INDUSTRY STANDARDS 106
7.2 SUSTAINABILITY IMPACT AND REGULATORY POLICY INITIATIVES 107
7.3 CERTIFICATIONS, LABELING, & ECO-STANDARDS 108
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 110
8.1 DECISION-MAKING PROCESS 110
8.2 BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA 110
8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 110
8.2.2 KEY BUYING CRITERIA, BY END USER 111
8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES 112
8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES 113
8.5 MARKET PROFITABILITY 113
9 IN VITRO TOXICOLOGY TESTING MARKET, BY OFFERING 114
9.1 INTRODUCTION 115
9.2 PRODUCTS 115
9.2.1 GROWING ADOPTION OF ADVANCED ASSAY PRODUCTS TO SUPPORT GROWTH 115
9.3 SERVICES 119
9.3.1 INCREASING FOCUS ON OUTSOURCING TOXICOLOGY TO AID GROWTH 119
10 IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY TYPE 123
10.1 INTRODUCTION 124
10.2 REAGENTS & CONSUMABLES 124
10.2.1 CULTURE REAGENTS, MEDIA, AND CONSUMABLES 127
10.2.1.1 Increasing adoption of IVTT workflows and recurring use of reagents to support growth 127
10.2.2 3D MODELS & TISSUE SYSTEMS 131
10.2.2.1 Support from regulatory agencies and wide usage to drive market growth 131
10.2.3 CELL LINES & PRIMARY CELLS 134
10.2.3.1 Emphasis on personalized medicine and driving quality improvement in commercially available cells to propel market 134
10.2.4 OTHER REAGENTS & CONSUMABLES 137
10.3 ASSAY KITS 140
10.3.1 ORGAN-SPECIFIC TOXICITY ASSAYS 143
10.3.1.1 Market is driven well-documented failure of generic cytotoxicity screens to predict organ-level adverse effects 143
10.3.2 CYTOTOXICITY ASSAYS 146
10.3.2.1 Cytotoxicity assays are the most universally applied assays in IVTT 146
10.3.3 GENOTOXICITY ASSAYS 149
10.3.3.1 Stringent regulatory mandates to support growth 149
10.3.4 OTHER ASSAYS 152
10.4 EQUIPMENT 155
10.4.1 DETECTION, IMAGING, AND ANALYTICAL SYSTEMS 158
10.4.1.1 Detection instruments 161
10.4.1.1.1 Growth is supported by the increasing volume of HTS workflows in pharmaceutical R&D and expanding use of functional safety pharmacology assays 161
10.4.1.2 Imaging systems 164
10.4.1.2.1 Demand for imaging systems in IVTT is being driven by the transition from single-endpoint to multiparametric, image-based toxicity assessment 164
10.4.1.3 Other instruments 168
10.4.1.4 Liquid handling & automation systems 171
10.4.1.4.1 Ease offered by automation and the important role of liquid handling in workflow to aid growth 171
10.4.1.5 Other instruments 174
10.5 SOFTWARE & INFORMATICS 177
10.5.1 DEMAND FOR AI/ML CAPABILITIES WITH TOXICOLOGY DATA TO DRIVE GROWTH 177
11 IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY TOXICITY ENDPOINT & TEST 181
11.1 INTRODUCTION 182
11.2 ORGAN TOXICITY TESTING 182
11.2.1 HEPATOTOXICITY 185
11.2.1.1 Regulatory mandates and focus on developing advanced liver models to support growth 185
11.2.2 OCULAR TOXICITY 189
11.2.2.1 Demand for cosmetics application to aid growth 189
11.2.3 CARDIOTOXICITY 192
11.2.3.1 Regulatory imperative for comprehensive cardiac safety profiling to drive growth 192
11.2.4 NEUROTOXICITY 195
11.2.4.1 Focus on developmental neurotoxicity and the expanding CNS drug pipelines to support growth 195
11.2.5 OTHER TOXICITY END POINTS 198
11.3 CYTOTOXICITY TESTING 201
11.3.1 A GROWING NUMBER OF NEW CLINICAL ENTITIES AND THE EXPANSION OF HTS PROGRAMS DRIVES MARKET 201
11.4 DERMAL TOXICITY & SKIN IRRITATION, CORROSION, AND SENSITIZATION 204
11.4.1 RISING AWARENESS AND BAN ON ANIMAL TESTING TO PROPEL MARKET 204
11.5 GENOTOXICITY TESTING 207
11.5.1 MANDATORY REQUIREMENT IN DRUG APPLICATIONS SUPPORTS MARKET GROWTH 207
11.6 OXIDATIVE STRESS AND MECHANISTIC TOXICITY 210
11.6.1 SHIFT TOWARD MECHANISTIC UNDERSTANDING TO DRIVE DEMAND FOR ASSAYS 210
11.7 OTHER TOXICITY ENDPOINTS & TESTS 213
12 IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY TECHNOLOGY 216
12.1 INTRODUCTION 217
12.2 CELL CULTURE TECHNOLOGIES 217
12.2.1 ADVANCING ADOPTION OF HUMAN-RELEVANT CELL CULTURE MODELS TO SUPPORT MARKET GROWTH 217
12.3 HIGH-THROUGHPUT & HIGH-CONTENT TECHNOLOGIES 220
12.3.1 EXPANDING HIGH-THROUGHPUT TOXICITY SCREENING TO ACCELERATE EARLY SAFETY ASSESSMENT 220
12.4 ORGANOTYPIC & MICROPHYSIOLOGICAL-BASED TECHNOLOGIES 223
12.4.1 GROWING FOCUS ON HUMAN-RELEVANT TOXICITY PREDICTION TO SUPPORT GROWTH 223
12.5 OMICS TECHNOLOGIES 226
12.5.1 INCREASING INTEGRATION OF OMICS-BASED TOXICOLOGY TO IMPROVE MECHANISTIC RISK ASSESSMENT 226
12.6 OTHER TECHNOLOGIES 229
13 IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY METHOD 232
13.1 INTRODUCTION 233
13.2 CELL-BASED TOXICITY TESTING 233
13.2.1 CELL-BASED TOXICITY TESTING HOLDS LARGEST MARKET SHARE 233
13.3 BIOCHEMICAL TOXICITY TESTING METHOD 237
13.3.1 SPEED AND REPRODUCIBILITY TO AID GROWTH 237
13.4 MOLECULAR & OMICS-BASED TOXICOLOGY METHOD 240
13.4.1 TRANSITION FROM SINGLE-ENDPOINT TO SYSTEMS-LEVEL TOXICOLOGICAL ASSESSMENT DRIVES DEMAND GROWTH 240
13.5 EX VIVO MODEL-BASED TOXICITY TESTING METHOD 243
13.5.1 INCREASING AVAILABILITY OF HUMAN DONOR TISSUE TO SUPPORT ADOPTION 243
13.6 IN SILICO/COMPUTATIONAL TOXICITY TESTING METHOD 247
13.6.1 ESCALATING COST AND TIME PRESSURES OF PHYSICAL TESTING TO AID GROWTH 247
13.7 OTHER METHODS 250
14 IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY END USER 253
14.1 INTRODUCTION 254
14.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 254
14.2.1 RISING GLOBAL PHARMACEUTICAL R&D EXPENDITURE SUPPORTING DRUG DISCOVERY EFFORTS 254
14.3 CONSUMER CARE COMPANIES 258
14.3.1 ANIMAL TESTING BANS TO SUPPORT SEGMENT GROWTH 258
14.4 CROS 261
14.4.1 HIGH CAPITAL AND OPERATIONAL COSTS OF MAINTAINING ADVANCED TECHNOLOGIES SUPPORT OUTSOURCING TO CROS 261
14.5 ACADEMIC & RESEARCH INSTITUTES 265
14.5.1 INCREASING GOVERNMENT FUNDING FOR ALTERNATIVE TESTING RESEARCH TO AID GROWTH 265
14.6 FOOD & BEVERAGE COMPANIES 268
14.6.1 GROWTH OF FUNCTIONAL FOODS, PLANT-BASED PROTEINS, AND NOVEL INGREDIENTS DRIVES DEMAND FOR TESTING 268
14.7 OTHER END USERS 272
15 IN VITRO TOXICOLOGY TESTING SERVICES MARKET, BY TYPE 276
15.1 INTRODUCTION 277
15.2 TOXICOLOGY TESTING SERVICES 277
15.2.1 ORGAN-SPECIFIC TOXICITY SERVICES 280
15.2.1.1 High reliance on outsourced services and growing demand for cardiotoxicity testing to drive market 280
15.2.2 CYTOTOXICITY TESTING SERVICES 283
15.2.2.1 Growing preclinical pipelines requiring cytotoxicity testing to propel demand 283
15.2.3 GENOTOXICITY TESTING SERVICES 286
15.2.3.1 Expanding impurity testing obligations to drive market 286
15.2.4 OTHER TOXICITY TESTING SERVICES 289
15.3 BIOLOGICAL MODEL & ASSAY DEVELOPMENT SERVICES 292
15.3.1 STRONG GROWTH SUPPORTED BY RISING DEMAND FOR APPLICATION-SPECIFIC MODELS AND ASSAYS 292
15.4 IMAGING & ANALYTICAL TOXICOLOGY SERVICES 295
15.4.1 CAPITAL-INTENSIVE INSTRUMENTATION AND SPECIALIZED REQUIREMENTS SUPPORT OUTSOURCING 295
15.5 DATA ANALYSIS, BIOINFORMATICS, AND PREDICTIVE TOXICOLOGY 298
15.5.1 INTEGRATION OF AI/ML AND RISING DATA COMPLEXITY PROPEL DEMAND 298
16 IN VITRO TOXICOLOGY TESTING SERVICES MARKET, BY METHOD 302
16.1 INTRODUCTION 303
16.2 CELL-BASED TOXICITY TESTING SERVICES 303
16.2.1 HIGH COST AND COMPLEXITY OF MAINTAINING ADVANCED CELL CULTURE INFRASTRUCTURE TO DRIVE GROWTH 303
16.3 BIOCHEMICAL TOXICITY TESTING SERVICES 307
16.3.1 GROWTH OF BIOLOGIC DRUG DEVELOPMENT IS DRIVING DEMAND FOR SPECIALIZED BIOCHEMICAL IMMUNOGENICITY TESTING SERVICES 307
16.4 IN SILICO/COMPUTATIONAL TOXICITY TESTING SERVICES 310
16.4.1 GROWING DATA COMPLEXITY, AI/ML MATURITY, AND REGULATORY ACCEPTANCE DRIVE GROWTH 310
16.5 MOLECULAR & OMICS-BASED TOXICOLOGY SERVICES 313
16.5.1 SPECIALIZED ANALYTICAL EXPERTISE REQUIREMENTS RELATED TO OMICS TO DRIVE GROWTH 313
16.6 EX VIVO MODEL-BASED TOXICITY TESTING SERVICES 317
16.6.1 USE OF EX VIVO MODELS FOR IN VITRO AND IN SILICO VALIDATION TO SUPPORT GROWTH 317
16.7 OTHER SERVICES 320
17 IN VITRO TOXICOLOGY TESTING SERVICE MARKET, BY END USER 323
17.1 INTRODUCTION 324
17.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 324
17.2.1 INCREASING COST AND COMPLEXITY OF MAINTAINING ADVANCED IVTT PLATFORMS IN-HOUSE TO SUPPORT GROWTH 324
17.3 CONSUMER CARE COMPANIES 328
17.3.1 REGULATION MANDATING IN VITRO-ONLY SAFETY ASSESSMENT IS SUPPORTING GROWTH 328
17.4 FOOD & BEVERAGE COMPANIES 331
17.4.1 EXPANDING SCOPE OF FUNCTIONAL FOOD AND ALTERNATIVE PROTEIN SAFETY ASSESSMENT TO SUPPORT GROWTH 331
17.5 ACADEMIC & RESEARCH INSTITUTES 335
17.5.1 OUTSOURCING OF SPECIALIZED SERVICES TO SUPPORT GROWTH 335
17.6 OTHER END USERS 338
18 IN VITRO TOXICOLOGY TESTING MARKET, BY REGION 342
18.1 INTRODUCTION 343
18.2 NORTH AMERICA 343
18.2.1 US 351
18.2.1.1 Growing focus on biomarker discovery and research in structure-based drug design to propel the market 351
18.2.2 CANADA 359
18.2.2.1 Strong support for R&D in pharmaceuticals and proteomics to boost market growth 359
18.3 EUROPE 367
18.3.1 GERMANY 374
18.3.1.1 Well-established pharmaceuticals industry to support market growth 374
18.3.2 UK 382
18.3.2.1 Rising focus on research activities and academia-industry partnerships to drive market 382
18.3.3 FRANCE 390
18.3.3.1 Increasing government funding for proteomics and genomics research to drive market 390
18.3.4 ITALY 398
18.3.4.1 Increasing life sciences research to propel market 398
18.3.5 SPAIN 405
18.3.5.1 Growing chemicals industry to support market growth 405
18.3.6 REST OF EUROPE 413
18.4 ASIA PACIFIC 420
18.4.1 CHINA 429
18.4.1.1 Increasing international pressure to ban animal testing methods to propel the market 429
18.4.2 JAPAN 436
18.4.2.1 Rising demand for technologically advanced research products to drive market 436
18.4.3 INDIA 443
18.4.3.1 Growing focus of universities on avoiding animal testing for cosmetic products to propel the market 443
18.4.4 SOUTH KOREA 451
18.4.4.1 Growing government focus on boosting pharmaceutical spending to propel market growth 451
18.4.5 AUSTRALIA 458
18.4.5.1 Growing pharmaceutical research to help market growth 458
18.4.6 REST OF ASIA PACIFIC 464
18.5 LATIN AMERICA 471
18.5.1 BRAZIL 479
18.5.1.1 Adoption of non-animal testing methods to propel market 479
18.5.2 MEXICO 486
18.5.2.1 Ban on animal testing for cosmetics to support market growth 486
18.5.3 REST OF LATIN AMERICA 493
18.6 MIDDLE EAST 500
18.6.1 GCC COUNTRIES 507
18.6.1.1 Saudi Arabia 515
18.6.1.1.1 Rising pharmaceutical R&D activities and regulatory focus on alternative testing methods to support market growth 515
18.6.1.2 United Arab Emirates (UAE) 522
18.6.1.2.1 Expanding biotechnology ecosystem and growing focus on advanced safety assessment technologies supporting market growth 522
18.6.1.3 Rest of GCC Countries 529
18.6.1.4 Rest of Middle East 536
18.6.2 AFRICA 543
18.6.2.1 Precision medicine initiatives to fuel market growth 543
19 COMPETITIVE LANDSCAPE 550
19.1 OVERVIEW 550
19.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 550
19.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN IN VITRO TOXICOLOGY TESTING MARKET 550
19.3 REVENUE SHARE ANALYSIS 552
19.4 MARKET SHARE ANALYSIS 553
19.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 555
19.5.1 STARS 555
19.5.2 EMERGING LEADERS 555
19.5.3 PERVASIVE PLAYERS 556
19.5.4 PARTICIPANTS 556
19.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025 557
19.5.5.1 Company footprint 557
19.5.5.2 Region footprint 558
19.5.5.3 Offering footprint 559
19.5.5.4 Technology footprint 560
19.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 561
19.6.1 PROGRESSIVE COMPANIES 561
19.6.2 STARTING BLOCKS 561
19.6.3 RESPONSIVE COMPANIES 561
19.6.4 DYNAMIC COMPANIES 561
19.6.5 COMPETITIVE BENCHMARKING OF KEY STARTUP/SME PLAYERS 563
19.6.5.1 Competitive benchmarking of key startups/SMEs 564
19.7 COMPANY VALUATION & FINANCIAL METRICS 565
19.7.1 FINANCIAL METRICS 565
19.7.2 COMPANY VALUATION 565
19.8 BRAND/PRODUCT COMPARISON 566
19.9 COMPETITIVE SCENARIO 567
19.9.1 PRODUCT LAUNCHES 567
19.9.2 DEALS 568
19.9.3 EXPANSIONS 568
20 COMPANY PROFILES 569
20.1 THERMO FISHER SCIENTIFIC INC. 569
20.1.1 BUSINESS OVERVIEW 569
20.1.1.1 Products/Services/Solutions offered 570
20.1.1.2 Recent developments 574
20.1.1.2.1 Product launches 574
20.1.1.2.2 Deals 575
20.1.1.2.3 Expansions 575
20.1.1.3 MnM view 576
20.1.1.3.1 Key strengths 576
20.1.1.3.2 Strategic choices 576
20.1.1.3.3 Weaknesses and competitive threats 576
20.1.2 AGILENT TECHNOLOGIES, INC. 577
20.1.2.1 Business overview 577
20.1.2.2 Products/Services/Solutions offered 578
20.1.2.3 Recent developments 580
20.1.2.3.1 Product launches & enhancements 580
20.1.2.3.2 Deals 581
20.1.2.4 MnM view 581
20.1.2.4.1 Key strengths 581
20.1.2.4.2 Strategic choices 581
20.1.2.4.3 Weaknesses and competitive threats 581
20.1.3 MERCK KGAA 582
20.1.3.1 Business overview 582
20.1.3.2 Products/Services/Solutions offered 583
20.1.3.3 Recent developments 585
20.1.3.3.1 Deals 585
20.1.3.4 MnM view 585
20.1.3.4.1 Key strengths 585
20.1.3.4.2 Strategic choices 585
20.1.3.4.3 Weaknesses and competitive threats 585
20.1.4 EUROFINS SCIENTIFIC 586
20.1.4.1 Business overview 586
20.1.4.2 Products/Services/Solutions offered 587
20.1.4.3 Recent developments 594
20.1.4.3.1 Expansions 594
20.1.5 CHARLES RIVER LABORATORIES 595
20.1.5.1 Business overview 595
20.1.5.2 Products/Services/Solutions offered 596
20.1.5.3 Recent developments 600
20.1.5.3.1 Product launches 600
20.1.5.3.2 Deals 600
20.1.5.3.3 Other developments 601
20.1.5.4 MnM view 601
20.1.5.4.1 Key strengths 601
20.1.5.4.2 Strategic choices 601
20.1.5.4.3 Weaknesses and competitive threats 601
20.1.6 LABORATORY CORPORATION OF AMERICA HOLDINGS 602
20.1.6.1 Business overview 602
20.1.6.2 Products/Services/Solutions offered 603
20.1.6.3 Recent developments 606
20.1.6.3.1 Deals 606
20.1.6.3.2 Expansions 606
20.1.6.3.3 Other developments 607
20.1.6.4 MnM view 607
20.1.6.4.1 Key strengths 607
20.1.6.4.2 Strategic choices 607
20.1.6.4.3 Weaknesses and competitive threats 607
20.1.7 SGS SA 608
20.1.7.1 Business overview 608
20.1.7.2 Products/Services/Solutions offered 609
20.1.7.3 Recent developments 612
20.1.7.3.1 Deals 612
20.1.7.3.2 Expansions 612
20.1.8 LONZA 613
20.1.8.1 Business overview 613
20.1.8.2 Products/Services/Solutions offered 614
20.1.9 REVVITY 616
20.1.9.1 Business overview 616
20.1.9.2 Products/Services/Solutions offered 617
20.1.9.3 Recent developments 619
20.1.9.3.1 Product launches 619
20.1.9.3.2 Other developments 619
20.1.10 BIO-RAD LABORATORIES, INC. 620
20.1.10.1 Business overview 620
20.1.10.2 Products/Services/Solutions offered 621
20.1.10.3 Recent developments 623
20.1.10.3.1 Product launches 623
20.1.10.3.2 Deals 624
20.1.11 EVOTEC SE 625
20.1.11.1 Business overview 625
20.1.11.2 Products/Services/Solutions offered 626
20.1.11.3 Recent developments 633
20.1.11.3.1 Deals 633
20.1.11.3.2 Other developments 633
20.1.12 NOVO HOLDINGS 634
20.1.12.1 Business overview 634
20.1.12.2 Products & services offered 634
20.1.13 INTERTEK GROUP PLC 635
20.1.13.1 Business overview 635
20.1.13.2 Products & services offered 637
20.1.14 INOTIV 638
20.1.14.1 Business overview 638
20.1.14.2 Products & services offered 639
20.1.15 PROMEGA CORPORATION 642
20.1.15.1 Business overview 642
20.1.15.2 Products & services offered 642
20.1.15.3 Recent developments 645
20.1.15.3.1 Deals 645
20.2 OTHER PLAYERS 646
20.2.1 BIOIVT 646
20.2.2 CREATIVE BIOLABS 647
20.2.3 MEDICILON 648
20.2.4 CREATIVE BIOARRAY 649
20.2.5 ARAGEN LIFE SCIENCES LTD. 650
20.2.6 ENZO BIOCHEM INC. 652
20.2.7 MICROBAC LABORATORIES, INC. 655
20.2.8 VIMTA LABS LTD. 657
20.2.9 PACIFIC BIOLABS, INC. 658
20.2.10 MB RESEARCH LABORATORIES 659
21 RESEARCH METHODOLOGY 660
21.1 RESEARCH DATA 660
21.1.1 SECONDARY DATA 661
21.1.2 PRIMARY DATA 661
21.2 MARKET SIZE ESTIMATION 662
21.2.1 GLOBAL IN VITRO TOXICOLOGY TESTING MARKET ESTIMATION, 2025 662
21.2.1.1 Key industry insights 666
21.3 GROWTH RATE ASSUMPTIONS/GROWTH FORECAST 667
21.4 MARKET BREAKDOWN AND DATA TRIANGULATION 670
21.5 RESEARCH ASSUMPTIONS 671
21.6 RESEARCH LIMITATIONS 672
21.7 RISK ANALYSIS 672
22 APPENDIX 673
22.1 DISCUSSION GUIDE 673
22.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 678
22.3 CUSTOMIZATION OPTIONS 680
22.4 RELATED REPORTS 680
22.5 AUTHOR DETAILS 681

LIST OF TABLES

TABLE 1 IN VITRO TOXICOLOGY TESTING MARKET: IMPACT ANALYSIS 73
TABLE 2 IN VITRO TOXICOLOGY TESTING MARKET: PORTER’S FIVE FORCES ANALYSIS 80
TABLE 3 IN VITRO TOXICOLOGY TESTING MARKET: ROLE IN ECOSYSTEM 84
TABLE 4 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY PRODUCT 86
TABLE 5 INDICATIVE SELLING PRICE, BY REGION, 2025 86
TABLE 6 IN VITRO TOXICOLOGY TESTING MARKET: KEY CONFERENCES & EVENTS,
2026–2027 87
TABLE 7 US-ADJUSTED RECIPROCAL TARIFF RATES 89
TABLE 8 INDICATIVE LIST OF PATENTS IN IN VITRO TOXICOLOGY TESTING MARKET, 2026 97
TABLE 9 CASE STUDIES OF AI IMPLEMENTATION IN IN VITRO TOXICOLOGY TESTING MARKET 99
TABLE 10 CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN IN VITRO TOXICOLOGY
TESTING MARKET 100
TABLE 11 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 102
TABLE 12 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 103
TABLE 13 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 104
TABLE 14 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 104
TABLE 15 COUNTRY-WISE REGULATORY SCENARIO FOR IN VITRO TOXICOLOGY TESTING PRODUCT & SERVICE PROVIDERS 105
TABLE 16 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY OFFERING (%) 111
TABLE 17 KEY BUYING CRITERIA, BY END USER 111
TABLE 18 IN VITRO TOXICOLOGY TESTING MARKET, BY OFFERING,
2024–2031(USD MILLION) 115
TABLE 19 IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY REGION,
2024–2031(USD MILLION) 116
TABLE 20 NORTH AMERICA: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET,
BY COUNTRY, 2024–2031(USD MILLION) 116
TABLE 21 EUROPE: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031(USD MILLION) 117
TABLE 22 ASIA PACIFIC: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031(USD MILLION) 117
TABLE 23 LATIN AMERICA: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET,
BY COUNTRY, 2024–2031(USD MILLION) 118
TABLE 24 MIDDLE EAST: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY REGION, 2024–2031(USD MILLION) 118
TABLE 25 GCC COUNTRIES: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET,
BY COUNTRY, 2024–2031(USD MILLION) 118
TABLE 26 IN VITRO TOXICOLOGY TESTING SERVICES MARKET, BY REGION,
2024–2031(USD MILLION) 120
TABLE 27 NORTH AMERICA: IN VITRO TOXICOLOGY TESTING SERVICES MARKET,
BY COUNTRY, 2024–2031(USD MILLION) 120
TABLE 28 EUROPE: IN VITRO TOXICOLOGY TESTING SERVICES MARKET, BY COUNTRY, 2024–2031(USD MILLION) 121
TABLE 29 ASIA PACIFIC: IN VITRO TOXICOLOGY TESTING SERVICES MARKET, BY COUNTRY, 2024–2031(USD MILLION) 121
TABLE 30 LATIN AMERICA: IN VITRO TOXICOLOGY TESTING SERVICES MARKET, BY COUNTRY, 2024–2031(USD MILLION) 122
TABLE 31 MIDDLE EAST: IN VITRO TOXICOLOGY TESTING SERVICES MARKET,
BY REGION, 2024–2031(USD MILLION) 122
TABLE 32 GCC COUNTRIES: IN VITRO TOXICOLOGY TESTING SERVICES MARKET,
BY COUNTRY, 2024–2031(USD MILLION) 122
TABLE 33 IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 124
TABLE 34 IVTT REAGENTS & CONSUMABLES MARKET, BY REGION,
2024–2031 (USD MILLION) 125
TABLE 35 NORTH AMERICA: IVTT REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 125
TABLE 36 EUROPE: IVTT REAGENTS & CONSUMABLES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 125
TABLE 37 ASIA PACIFIC: IVTT REAGENTS & CONSUMABLES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 126
TABLE 38 LATIN AMERICA: IVTT REAGENTS & CONSUMABLES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 126
TABLE 39 MIDDLE EAST: IVTT REAGENTS & CONSUMABLES MARKET, BY REGION, 2024–2031 (USD MILLION) 126
TABLE 40 GCC COUNTRIES: IVTT REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 127
TABLE 41 IVTT REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 127
TABLE 42 CULTURE REAGENTS, MEDIA, AND CONSUMABLES MARKET, BY REGION,
2024–2031 (USD MILLION) 128
TABLE 43 NORTH AMERICA: CULTURE REAGENTS, MEDIA, AND CONSUMABLES MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 128
TABLE 44 EUROPE: CULTURE REAGENTS, MEDIA, AND CONSUMABLES MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 129
TABLE 45 ASIA PACIFIC: CULTURE REAGENTS, MEDIA, AND CONSUMABLES MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 129
TABLE 46 LATIN AMERICA: CULTURE REAGENTS, MEDIA, AND CONSUMABLES MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 130
TABLE 47 MIDDLE EAST: CULTURE REAGENTS, MEDIA, AND CONSUMABLES MARKET,
BY REGION, 2024–2031 (USD MILLION) 130
TABLE 48 GCC COUNTRIES: CULTURE REAGENTS, MEDIA, AND CONSUMABLES MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 130
TABLE 49 3D MODELS & TISSUE SYSTEMS MARKET, BY REGION, 2024–2031 (USD MILLION) 132
TABLE 50 NORTH AMERICA: 3D MODELS & TISSUE SYSTEMS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 132
TABLE 51 EUROPE: 3D MODELS & TISSUE SYSTEMS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 132
TABLE 52 ASIA PACIFIC: 3D MODELS & TISSUE SYSTEMS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 133
TABLE 53 LATIN AMERICA: 3D MODELS & TISSUE SYSTEMS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 133
TABLE 54 MIDDLE EAST: 3D MODELS & TISSUE SYSTEMS MARKET, BY REGION,
2024–2031 (USD MILLION) 133
TABLE 55 GCC COUNTRIES: 3D MODELS & TISSUE SYSTEMS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 134
TABLE 56 CELL LINES & PRIMARY CELLS MARKET, BY REGION, 2024–2031 (USD MILLION) 135
TABLE 57 NORTH AMERICA: CELL LINES & PRIMARY CELLS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 135
TABLE 58 EUROPE: CELL LINES & PRIMARY CELLS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 135
TABLE 59 ASIA PACIFIC: CELL LINES & PRIMARY CELLS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 136
TABLE 60 LATIN AMERICA: CELL LINES & PRIMARY CELLS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 136
TABLE 61 MIDDLE EAST: CELL LINES & PRIMARY CELLS MARKET, BY REGION,
2024–2031 (USD MILLION) 136
TABLE 62 GCC COUNTRIES: CELL LINES & PRIMARY CELLS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 137
TABLE 63 OTHER REAGENTS & CONSUMABLES MARKET, BY REGION,
2024–2031 (USD MILLION) 138
TABLE 64 NORTH AMERICA: OTHER REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 138
TABLE 65 EUROPE: OTHER REAGENTS & CONSUMABLES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 138
TABLE 66 ASIA PACIFIC: OTHER REAGENTS & CONSUMABLES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 139
TABLE 67 LATIN AMERICA: OTHER REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 139
TABLE 68 MIDDLE EAST: OTHER REAGENTS & CONSUMABLES MARKET, BY REGION,
2024–2031 (USD MILLION) 139
TABLE 69 GCC COUNTRIES: OTHER REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 140
TABLE 70 IVTT ASSAY KITS MARKET, BY REGION, 2024–2031 (USD MILLION) 140
TABLE 71 NORTH AMERICA: IVTT ASSAY KITS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 140
TABLE 72 EUROPE: IVTT ASSAY KITS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 141
TABLE 73 ASIA PACIFIC: IVTT ASSAY KITS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 141
TABLE 74 LATIN AMERICA: IVTT ASSAY KITS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 142
TABLE 75 MIDDLE EAST: IVTT ASSAY KITS MARKET, BY REGION, 2024–2031 (USD MILLION) 142
TABLE 76 GCC COUNTRIES: IVTT ASSAY KITS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 142
TABLE 77 IVTT ASSAY KITS MARKET, BY TYPE, 2024–2031 (USD MILLION) 143
TABLE 78 ORGAN-SPECIFIC TOXICITY ASSAYS MARKET, BY REGION,
2024–2031 (USD MILLION) 144
TABLE 79 NORTH AMERICA: ORGAN-SPECIFIC TOXICITY ASSAYS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 144
TABLE 80 EUROPE: ORGAN-SPECIFIC TOXICITY ASSAYS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 144
TABLE 81 ASIA PACIFIC: ORGAN-SPECIFIC TOXICITY ASSAYS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 145
TABLE 82 LATIN AMERICA: ORGAN-SPECIFIC TOXICITY ASSAYS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 145
TABLE 83 MIDDLE EAST: ORGAN-SPECIFIC TOXICITY ASSAYS MARKET, BY REGION,
2024–2031 (USD MILLION) 145
TABLE 84 GCC COUNTRIES: ORGAN-SPECIFIC TOXICITY ASSAYS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 146
TABLE 85 CYTOTOXICITY ASSAYS MARKET, BY REGION, 2024–2031 (USD MILLION) 147
TABLE 86 NORTH AMERICA: CYTOTOXICITY ASSAYS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 147
TABLE 87 EUROPE: CYTOTOXICITY ASSAYS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 147
TABLE 88 ASIA PACIFIC: CYTOTOXICITY ASSAYS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 148
TABLE 89 LATIN AMERICA: CYTOTOXICITY ASSAYS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 148
TABLE 90 MIDDLE EAST: CYTOTOXICITY ASSAYS MARKET, BY REGION,
2024–2031 (USD MILLION) 148
TABLE 91 GCC COUNTRIES: CYTOTOXICITY ASSAYS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 149
TABLE 92 GENOTOXICITY ASSAYS MARKET, BY REGION, 2024–2031 (USD MILLION) 150
TABLE 93 NORTH AMERICA: GENOTOXICITY ASSAYS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 150
TABLE 94 EUROPE: GENOTOXICITY ASSAYS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 150
TABLE 95 ASIA PACIFIC: GENOTOXICITY ASSAYS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 151
TABLE 96 LATIN AMERICA: GENOTOXICITY ASSAYS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 151
TABLE 97 MIDDLE EAST: GENOTOXICITY ASSAYS MARKET, BY REGION,
2024–2031 (USD MILLION) 151
TABLE 98 GCC COUNTRIES: GENOTOXICITY ASSAYS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 152
TABLE 99 OTHER ASSAYS MARKET, BY REGION, 2024–2031 (USD MILLION) 153
TABLE 100 NORTH AMERICA: OTHER ASSAYS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 153
TABLE 101 EUROPE: OTHER ASSAYS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 153
TABLE 102 ASIA PACIFIC: OTHER ASSAYS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 154
TABLE 103 LATIN AMERICA: OTHER ASSAYS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 154
TABLE 104 MIDDLE EAST: OTHER ASSAYS MARKET, BY REGION, 2024–2031 (USD MILLION) 154
TABLE 105 GCC COUNTRIES: OTHER ASSAYS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 155
TABLE 106 IVTT EQUIPMENT MARKET, BY REGION, 2024–2031 (USD MILLION) 155
TABLE 107 NORTH AMERICA: IVTT EQUIPMENT MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 155
TABLE 108 EUROPE: IVTT EQUIPMENT MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 156
TABLE 109 ASIA PACIFIC: IVTT EQUIPMENT MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 156
TABLE 110 LATIN AMERICA: IVTT EQUIPMENT MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 157
TABLE 111 MIDDLE EAST: IVTT EQUIPMENT MARKET, BY REGION, 2024–2031 (USD MILLION) 157
TABLE 112 GCC COUNTRIES: IVTT EQUIPMENT MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 157
TABLE 113 IVTT EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 158
TABLE 114 DETECTION, IMAGING, AND ANALYTICAL SYSTEMS MARKET, BY REGION,
2024–2031 (USD MILLION) 158
TABLE 115 NORTH AMERICA: DETECTION, IMAGING, AND ANALYTICAL SYSTEMS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 159
TABLE 116 EUROPE: DETECTION, IMAGING, AND ANALYTICAL SYSTEMS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 159
TABLE 117 ASIA PACIFIC: DETECTION, IMAGING, AND ANALYTICAL SYSTEMS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 160
TABLE 118 LATIN AMERICA: DETECTION, IMAGING, AND ANALYTICAL SYSTEMS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 160
TABLE 119 MIDDLE EAST: DETECTION, IMAGING, AND ANALYTICAL SYSTEMS MARKET,
BY REGION, 2024–2031 (USD MILLION) 160
TABLE 120 GCC COUNTRIES: DETECTION, IMAGING, AND ANALYTICAL SYSTEMS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 161
TABLE 121 DETECTION, IMAGING, AND ANALYTICAL SYSTEMS MARKET, BY TYPE,
2024–2031 (USD MILLION) 161
TABLE 122 DETECTION INSTRUMENTS MARKET, BY REGION, 2024–2031 (USD MILLION) 162
TABLE 123 NORTH AMERICA: DETECTION INSTRUMENTS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 162
TABLE 124 EUROPE: DETECTION INSTRUMENTS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 162
TABLE 125 ASIA PACIFIC: DETECTION INSTRUMENTS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 163
TABLE 126 LATIN AMERICA: DETECTION INSTRUMENTS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 163
TABLE 127 MIDDLE EAST: DETECTION INSTRUMENTS MARKET, BY REGION,
2024–2031 (USD MILLION) 163
TABLE 128 GCC COUNTRIES: DETECTION INSTRUMENTS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 164
TABLE 129 IMAGING SYSTEMS MARKET, BY REGION, 2024–2031 (USD MILLION) 165
TABLE 130 NORTH AMERICA: IMAGING SYSTEMS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 165
TABLE 131 EUROPE: IMAGING SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 166
TABLE 132 ASIA PACIFIC: IMAGING SYSTEMS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 166
TABLE 133 LATIN AMERICA: IMAGING SYSTEMS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 167
TABLE 134 MIDDLE EAST: IMAGING SYSTEMS MARKET, BY REGION,
2024–2031 (USD MILLION) 167
TABLE 135 GCC COUNTRIES: IMAGING SYSTEMS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 167
TABLE 136 OTHER INSTRUMENTS MARKET, BY REGION, 2024–2031 (USD MILLION) 168
TABLE 137 NORTH AMERICA: OTHER INSTRUMENTS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 168
TABLE 138 EUROPE: OTHER INSTRUMENTS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 169
TABLE 139 ASIA PACIFIC: OTHER INSTRUMENTS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 169
TABLE 140 LATIN AMERICA: OTHER INSTRUMENTS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 170
TABLE 141 MIDDLE EAST: OTHER INSTRUMENTS MARKET, BY REGION,
2024–2031 (USD MILLION) 170
TABLE 142 GCC COUNTRIES: OTHER INSTRUMENTS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 170
TABLE 143 LIQUID HANDLING & AUTOMATION SYSTEMS MARKET, BY REGION,
2024–2031 (USD MILLION) 171
TABLE 144 NORTH AMERICA: LIQUID HANDLING & AUTOMATION SYSTEMS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 172
TABLE 145 EUROPE: LIQUID HANDLING & AUTOMATION SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 172
TABLE 146 ASIA PACIFIC: LIQUID HANDLING & AUTOMATION SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 173
TABLE 147 LATIN AMERICA: LIQUID HANDLING & AUTOMATION SYSTEMS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 173
TABLE 148 MIDDLE EAST: LIQUID HANDLING & AUTOMATION SYSTEMS MARKET, BY REGION, 2024–2031 (USD MILLION) 173
TABLE 149 GCC COUNTRIES: LIQUID HANDLING & AUTOMATION SYSTEMS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 174
TABLE 150 OTHER INSTRUMENTS MARKET, BY REGION, 2024–2031 (USD MILLION) 174
TABLE 151 NORTH AMERICA: OTHER EQUIPMENT MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 175
TABLE 152 EUROPE: OTHER EQUIPMENT MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 175
TABLE 153 ASIA PACIFIC: OTHER EQUIPMENT MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 176
TABLE 154 LATIN AMERICA: OTHER EQUIPMENT MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 176
TABLE 155 MIDDLE EAST: OTHER EQUIPMENT MARKET, BY REGION,
2024–2031 (USD MILLION) 176
TABLE 156 GCC COUNTRIES: OTHER EQUIPMENT MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 177
TABLE 157 IVTT SOFTWARE & INFORMATICS MARKET, BY REGION,
2024–2031 (USD MILLION) 178
TABLE 158 NORTH AMERICA: IVTT SOFTWARE & INFORMATICS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 178
TABLE 159 EUROPE: IVTT SOFTWARE & INFORMATICS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 179
TABLE 160 ASIA PACIFIC: IVTT SOFTWARE & INFORMATICS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 179
TABLE 161 LATIN AMERICA: IVTT SOFTWARE & INFORMATICS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 180
TABLE 162 MIDDLE EAST: IVTT SOFTWARE & INFORMATICS MARKET, BY REGION,
2024–2031 (USD MILLION) 180
TABLE 163 GCC COUNTRIES: IVTT SOFTWARE & INFORMATICS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 180
TABLE 164 IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY TOXICITY ENDPOINT & TEST, 2024–2031 (USD MILLION) 182
TABLE 165 ORGAN TOXICITY TESTING MARKET, BY REGION, 2024–2031 (USD MILLION) 183
TABLE 166 NORTH AMERICA: ORGAN TOXICITY TESTING MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 183
TABLE 167 EUROPE: ORGAN TOXICITY TESTING MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 183
TABLE 168 ASIA PACIFIC: ORGAN TOXICITY TESTING MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 184
TABLE 169 LATIN AMERICA: ORGAN TOXICITY TESTING MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 184
TABLE 170 MIDDLE EAST: ORGAN TOXICITY TESTING MARKET, BY REGION,
2024–2031 (USD MILLION) 184
TABLE 171 GCC COUNTRIES: ORGAN TOXICITY TESTING MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 185
TABLE 172 ORGAN TOXICITY TESTING MARKET, BY TYPE, 2024–2031 (USD MILLION) 185
TABLE 173 HEPATOTOXICITY MARKET, BY REGION, 2024–2031 (USD MILLION) 186
TABLE 174 NORTH AMERICA: HEPATOTOXICITY MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 186
TABLE 175 EUROPE: HEPATOTOXICITY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 187
TABLE 176 ASIA PACIFIC: HEPATOTOXICITY MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 187
TABLE 177 LATIN AMERICA: HEPATOTOXICITY MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 188
TABLE 178 MIDDLE EAST: HEPATOTOXICITY MARKET, BY REGION, 2024–2031 (USD MILLION) 188
TABLE 179 GCC COUNTRIES: HEPATOTOXICITY MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 188
TABLE 180 OCULAR TOXICITY MARKET, BY REGION, 2024–2031 (USD MILLION) 189
TABLE 181 NORTH AMERICA: OCULAR TOXICITY MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 189
TABLE 182 EUROPE: OCULAR TOXICITY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 190
TABLE 183 ASIA PACIFIC: OCULAR TOXICITY MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 190
TABLE 184 LATIN AMERICA: OCULAR TOXICITY MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 191
TABLE 185 MIDDLE EAST: OCULAR TOXICITY MARKET, BY REGION,
2024–2031 (USD MILLION) 191
TABLE 186 GCC COUNTRIES: OCULAR TOXICITY MARKET, BY COUNTRY
, 2024–2031 (USD MILLION) 191
TABLE 187 CARDIOTOXICITY MARKET, BY REGION, 2024–2031 (USD MILLION) 192
TABLE 188 NORTH AMERICA: CARDIOTOXICITY MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 192
TABLE 189 EUROPE: CARDIOTOXICITY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 193
TABLE 190 ASIA PACIFIC: CARDIOTOXICITY MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 193
TABLE 191 LATIN AMERICA: CARDIOTOXICITY MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 194
TABLE 192 MIDDLE EAST: CARDIOTOXICITY MARKET, BY REGION, 2024–2031 (USD MILLION) 194
TABLE 193 GCC COUNTRIES: CARDIOTOXICITY MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 194
TABLE 194 NEUROTOXICITY MARKET, BY REGION, 2024–2031 (USD MILLION) 195
TABLE 195 NORTH AMERICA: NEUROTOXICITY MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 195
TABLE 196 EUROPE: NEUROTOXICITY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 196
TABLE 197 ASIA PACIFIC: NEUROTOXICITY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 196
TABLE 198 LATIN AMERICA: NEUROTOXICITY MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 197
TABLE 199 MIDDLE EAST: NEUROTOXICITY MARKET, BY REGION, 2024–2031 (USD MILLION) 197
TABLE 200 GCC COUNTRIES: NEUROTOXICITY MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 197
TABLE 201 OTHER TOXICITY END POINTS MARKET, BY REGION, 2024–2031 (USD MILLION) 198
TABLE 202 NORTH AMERICA: OTHER TOXICITY END POINTS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 198
TABLE 203 EUROPE: OTHER TOXICITY END POINTS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 199
TABLE 204 ASIA PACIFIC: OTHER TOXICITY END POINTS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 199
TABLE 205 LATIN AMERICA: OTHER TOXICITY END POINTS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 200
TABLE 206 MIDDLE EAST: OTHER TOXICITY END POINTS MARKET, BY REGION,
2024–2031 (USD MILLION) 200
TABLE 207 GCC COUNTRIES: OTHER TOXICITY END POINTS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 200
TABLE 208 CYTOTOXICITY TESTING MARKET, BY REGION, 2024–2031 (USD MILLION) 201
TABLE 209 NORTH AMERICA: CYTOTOXICITY TESTING MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 201
TABLE 210 EUROPE: CYTOTOXICITY TESTING MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 202
TABLE 211 ASIA PACIFIC: CYTOTOXICITY TESTING MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 202
TABLE 212 LATIN AMERICA: CYTOTOXICITY TESTING MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 203
TABLE 213 MIDDLE EAST: CYTOTOXICITY TESTING MARKET, BY REGION,
2024–2031 (USD MILLION) 203
TABLE 214 GCC COUNTRIES: CYTOTOXICITY TESTING MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 203
TABLE 215 DERMAL TOXICITY & SKIN IRRITATION, CORROSION, AND SENSITIZATION MARKET, BY REGION, 2024–2031 (USD MILLION) 204
TABLE 216 NORTH AMERICA: DERMAL TOXICITY & SKIN IRRITATION, CORROSION, AND SENSITIZATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 204
TABLE 217 EUROPE: DERMAL TOXICITY & SKIN IRRITATION, CORROSION, AND SENSITIZATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 205
TABLE 218 ASIA PACIFIC: DERMAL TOXICITY & SKIN IRRITATION, CORROSION, AND SENSITIZATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 205
TABLE 219 LATIN AMERICA: DERMAL TOXICITY & SKIN IRRITATION, CORROSION, AND SENSITIZATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 206
TABLE 220 MIDDLE EAST: DERMAL TOXICITY & SKIN IRRITATION, CORROSION, AND SENSITIZATION MARKET, BY REGION, 2024–2031 (USD MILLION) 206
TABLE 221 GCC COUNTRIES: DERMAL TOXICITY & SKIN IRRITATION, CORROSION, AND SENSITIZATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 206
TABLE 222 GENOTOXICITY TESTING MARKET, BY REGION, 2024–2031 (USD MILLION) 207
TABLE 223 NORTH AMERICA: GENOTOXICITY TESTING MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 207
TABLE 224 EUROPE: GENOTOXICITY TESTING MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 208
TABLE 225 ASIA PACIFIC: GENOTOXICITY TESTING MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 208
TABLE 226 LATIN AMERICA: GENOTOXICITY TESTING MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 209
TABLE 227 MIDDLE EAST: GENOTOXICITY TESTING MARKET, BY REGION,
2024–2031 (USD MILLION) 209
TABLE 228 GCC COUNTRIES: GENOTOXICITY TESTING MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 209
TABLE 229 OXIDATIVE STRESS AND MECHANISTIC TOXICITY MARKET, BY REGION,
2024–2031 (USD MILLION) 210
TABLE 230 NORTH AMERICA: OXIDATIVE STRESS AND MECHANISTIC TOXICITY MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 210
TABLE 231 EUROPE: OXIDATIVE STRESS AND MECHANISTIC TOXICITY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 211
TABLE 232 ASIA PACIFIC: OXIDATIVE STRESS AND MECHANISTIC TOXICITY MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 211
TABLE 233 LATIN AMERICA: OXIDATIVE STRESS AND MECHANISTIC TOXICITY MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 212
TABLE 234 MIDDLE EAST: OXIDATIVE STRESS AND MECHANISTIC TOXICITY MARKET,
BY REGION, 2024–2031 (USD MILLION) 212
TABLE 235 GCC COUNTRIES: OXIDATIVE STRESS AND MECHANISTIC TOXICITY MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 212
TABLE 236 OTHER TOXICITY ENDPOINTS & TESTS MARKET, BY REGION,
2024–2031 (USD MILLION) 213
TABLE 237 NORTH AMERICA: OTHER TOXICITY ENDPOINTS & TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 213
TABLE 238 EUROPE: OTHER TOXICITY ENDPOINTS & TESTS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 214
TABLE 239 ASIA PACIFIC: OTHER TOXICITY ENDPOINTS & TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 214
TABLE 240 LATIN AMERICA: OTHER TOXICITY ENDPOINTS & TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 215
TABLE 241 MIDDLE EAST: OTHER TOXICITY ENDPOINTS & TESTS MARKET, BY REGION,
2024–2031 (USD MILLION) 215
TABLE 242 GCC COUNTRIES: OTHER TOXICITY ENDPOINTS & TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 215
TABLE 243 IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 217
TABLE 244 CELL CULTURE TECHNOLOGIES MARKET, BY REGION, 2024–2031 (USD MILLION) 218
TABLE 245 NORTH AMERICA: CELL CULTURE TECHNOLOGIES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 218
TABLE 246 EUROPE: CELL CULTURE TECHNOLOGIES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 218
TABLE 247 ASIA PACIFIC: CELL CULTURE TECHNOLOGIES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 219
TABLE 248 LATIN AMERICA: CELL CULTURE TECHNOLOGIES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 219
TABLE 249 MIDDLE EAST: CELL CULTURE TECHNOLOGIES MARKET, BY REGION,
2024–2031 (USD MILLION) 219
TABLE 250 GCC COUNTRIES: CELL CULTURE TECHNOLOGIES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 220
TABLE 251 HIGH-THROUGHPUT & HIGH-CONTENT TECHNOLOGIES MARKET, BY REGION, 2024–2031 (USD MILLION) 220
TABLE 252 NORTH AMERICA: HIGH-THROUGHPUT & HIGH-CONTENT TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 221
TABLE 253 EUROPE: HIGH-THROUGHPUT & HIGH-CONTENT TECHNOLOGIES MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 221
TABLE 254 ASIA PACIFIC: HIGH-THROUGHPUT & HIGH-CONTENT TECHNOLOGIES MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 222
TABLE 255 LATIN AMERICA: HIGH-THROUGHPUT & HIGH-CONTENT TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 222
TABLE 256 MIDDLE EAST: HIGH-THROUGHPUT & HIGH-CONTENT TECHNOLOGIES MARKET, BY REGION, 2024–2031 (USD MILLION) 222
TABLE 257 GCC COUNTRIES: HIGH-THROUGHPUT & HIGH-CONTENT TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 223
TABLE 258 ORGANOTYPIC & MICROPHYSIOLOGICAL-BASED TECHNOLOGIES MARKET, BY REGION, 2024–2031 (USD MILLION) 223
TABLE 259 NORTH AMERICA: ORGANOTYPIC & MICROPHYSIOLOGICAL-BASED TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 224
TABLE 260 EUROPE: ORGANOTYPIC & MICROPHYSIOLOGICAL-BASED TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 224
TABLE 261 ASIA PACIFIC: ORGANOTYPIC & MICROPHYSIOLOGICAL-BASED TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 225
TABLE 262 LATIN AMERICA: ORGANOTYPIC & MICROPHYSIOLOGICAL-BASED TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 225
TABLE 263 MIDDLE EAST: ORGANOTYPIC & MICROPHYSIOLOGICAL-BASED TECHNOLOGIES MARKET, BY REGION, 2024–2031 (USD MILLION) 225
TABLE 264 GCC COUNTRIES: ORGANOTYPIC & MICROPHYSIOLOGICAL-BASED TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 226
TABLE 265 OMICS TECHNOLOGIES MARKET, BY REGION, 2024–2031 (USD MILLION) 226
TABLE 266 NORTH AMERICA: OMICS TECHNOLOGIES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 227
TABLE 267 EUROPE: OMICS TECHNOLOGIES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 227
TABLE 268 ASIA PACIFIC: OMICS TECHNOLOGIES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 228
TABLE 269 LATIN AMERICA: OMICS TECHNOLOGIES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 228
TABLE 270 MIDDLE EAST: OMICS TECHNOLOGIES MARKET, BY REGION,
2024–2031 (USD MILLION) 228
TABLE 271 GCC COUNTRIES: OMICS TECHNOLOGIES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 229
TABLE 272 OTHER TECHNOLOGIES MARKET, BY REGION, 2024–2031 (USD MILLION) 229
TABLE 273 NORTH AMERICA: OTHER TECHNOLOGIES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 230
TABLE 274 EUROPE: OTHER TECHNOLOGIES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 230
TABLE 275 ASIA PACIFIC: OTHER TECHNOLOGIES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 230
TABLE 276 LATIN AMERICA: OTHER TECHNOLOGIES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 231
TABLE 277 MIDDLE EAST: OTHER TECHNOLOGIES MARKET, BY REGION,
2024–2031 (USD MILLION) 231
TABLE 278 GCC COUNTRIES: OTHER TECHNOLOGIES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 231
TABLE 279 IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY METHOD,
2024–2031 (USD MILLION) 233
TABLE 280 CELL-BASED TOXICITY TESTING METHOD MARKET, BY REGION,
2024–2031 (USD MILLION) 234
TABLE 281 NORTH AMERICA: CELL-BASED TOXICITY TESTING METHOD MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 234
TABLE 282 EUROPE: CELL-BASED TOXICITY TESTING METHOD MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 235
TABLE 283 ASIA PACIFIC: CELL-BASED TOXICITY TESTING METHOD MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 235
TABLE 284 LATIN AMERICA: CELL-BASED TOXICITY TESTING METHOD MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 236
TABLE 285 MIDDLE EAST: CELL-BASED TOXICITY TESTING METHOD MARKET, BY REGION, 2024–2031 (USD MILLION) 236
TABLE 286 GCC COUNTRIES: CELL-BASED TOXICITY TESTING METHOD MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 236
TABLE 287 BIOCHEMICAL TOXICITY TESTING METHOD MARKET, BY REGION,
2024–2031 (USD MILLION) 237
TABLE 288 NORTH AMERICA: BIOCHEMICAL TOXICITY TESTING METHOD MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 237
TABLE 289 EUROPE: BIOCHEMICAL TOXICITY TESTING METHOD MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 238
TABLE 290 ASIA PACIFIC: BIOCHEMICAL TOXICITY TESTING METHOD MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 238
TABLE 291 LATIN AMERICA: BIOCHEMICAL TOXICITY TESTING METHOD MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 239
TABLE 292 MIDDLE EAST: BIOCHEMICAL TOXICITY TESTING METHOD MARKET, BY REGION, 2024–2031 (USD MILLION) 239
TABLE 293 GCC COUNTRIES: BIOCHEMICAL TOXICITY TESTING METHOD MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 239
TABLE 294 MOLECULAR & OMICS-BASED TOXICOLOGY METHOD MARKET, BY REGION,
2024–2031 (USD MILLION) 240
TABLE 295 NORTH AMERICA: MOLECULAR & OMICS-BASED TOXICOLOGY METHOD MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 241
TABLE 296 EUROPE: MOLECULAR & OMICS-BASED TOXICOLOGY METHOD MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 241
TABLE 297 ASIA PACIFIC: MOLECULAR & OMICS-BASED TOXICOLOGY METHOD MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 242
TABLE 298 LATIN AMERICA: MOLECULAR & OMICS-BASED TOXICOLOGY METHOD MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 242
TABLE 299 MIDDLE EAST: MOLECULAR & OMICS-BASED TOXICOLOGY METHOD MARKET,
BY REGION, 2024–2031 (USD MILLION) 242
TABLE 300 GCC COUNTRIES: MOLECULAR & OMICS-BASED TOXICOLOGY METHOD MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 243
TABLE 301 EX VIVO MODEL-BASED TOXICITY TESTING METHOD MARKET, BY REGION,
2024–2031 (USD MILLION) 244
TABLE 302 NORTH AMERICA: EX VIVO MODEL-BASED TOXICITY TESTING METHOD MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 244
TABLE 303 EUROPE: EX VIVO MODEL-BASED TOXICITY TESTING METHOD MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 245
TABLE 304 ASIA PACIFIC: EX VIVO MODEL-BASED TOXICITY TESTING METHOD MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 245
TABLE 305 LATIN AMERICA: EX VIVO MODEL-BASED TOXICITY TESTING METHOD MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 246
TABLE 306 MIDDLE EAST: EX VIVO MODEL-BASED TOXICITY TESTING METHOD MARKET,
BY REGION, 2024–2031 (USD MILLION) 246
TABLE 307 GCC COUNTRIES: EX VIVO MODEL-BASED TOXICITY TESTING METHOD MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 246
TABLE 308 IN SILICO/COMPUTATIONAL TOXICITY TESTING METHOD MARKET, BY REGION, 2024–2031 (USD MILLION) 247
TABLE 309 NORTH AMERICA: IN SILICO/COMPUTATIONAL TOXICITY TESTING METHOD MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 247
TABLE 310 EUROPE: IN SILICO/COMPUTATIONAL TOXICITY TESTING METHOD MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 248
TABLE 311 ASIA PACIFIC: IN SILICO/COMPUTATIONAL TOXICITY TESTING METHOD MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 248
TABLE 312 LATIN AMERICA: IN SILICO/COMPUTATIONAL TOXICITY TESTING METHOD MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 249
TABLE 313 MIDDLE EAST: IN SILICO/COMPUTATIONAL TOXICITY TESTING METHOD MARKET, BY REGION, 2024–2031 (USD MILLION) 249
TABLE 314 GCC COUNTRIES: IN SILICO/COMPUTATIONAL TOXICITY TESTING METHOD MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 249
TABLE 315 OTHER IN VITRO TOXICOLOGY TESTING METHODS MARKET, BY REGION,
2024–2031 (USD MILLION) 250
TABLE 316 NORTH AMERICA: OTHER IN VITRO TOXICOLOGY TESTING METHODS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 250
TABLE 317 EUROPE: OTHER IN VITRO TOXICOLOGY TESTING METHODS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 251
TABLE 318 ASIA PACIFIC: OTHER IN VITRO TOXICOLOGY TESTING METHODS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 251
TABLE 319 LATIN AMERICA: OTHER IN VITRO TOXICOLOGY TESTING METHODS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 252
TABLE 320 MIDDLE EAST: OTHER IN VITRO TOXICOLOGY TESTING METHODS MARKET,
BY REGION, 2024–2031 (USD MILLION) 252
TABLE 321 GCC COUNTRIES: OTHER METHODS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 252
TABLE 322 IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY END USER,
2024–2031 (USD MILLION) 254
TABLE 323 IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024–2031 (USD MILLION) 255
TABLE 324 NORTH AMERICA: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY,
2024–2031 (USD MILLION) 255
TABLE 325 EUROPE: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY,
2024–2031 (USD MILLION) 256
TABLE 326 ASIA PACIFIC: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY,
2024–2031 (USD MILLION) 256
TABLE 327 LATIN AMERICA: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY,
2024–2031 (USD MILLION) 257
TABLE 328 MIDDLE EAST: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION,
2024–2031 (USD MILLION) 257
TABLE 329 GCC COUNTRIES: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY,
2024–2031 (USD MILLION) 257
TABLE 330 IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET FOR CONSUMER CARE COMPANIES, BY REGION, 2024–2031 (USD MILLION) 258
TABLE 331 NORTH AMERICA: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET FOR CONSUMER CARE COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 259
TABLE 332 EUROPE: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET FOR CONSUMER CARE COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 259
TABLE 333 ASIA PACIFIC: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET FOR CONSUMER CARE COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 260
TABLE 334 LATIN AMERICA: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET FOR CONSUMER CARE COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 260
TABLE 335 MIDDLE EAST: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET FOR CONSUMER CARE COMPANIES, BY REGION, 2024–2031 (USD MILLION) 260
TABLE 336 GCC COUNTRIES: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET FOR CONSUMER CARE COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 261
TABLE 337 IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET FOR CROS, BY REGION, 2024–2031 (USD MILLION) 262
TABLE 338 NORTH AMERICA: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET FOR CROS, BY COUNTRY, 2024–2031 (USD MILLION) 262
TABLE 339 EUROPE: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET FOR CROS,
BY COUNTRY, 2024–2031 (USD MILLION) 263
TABLE 340 ASIA PACIFIC: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET FOR CROS,
BY COUNTRY, 2024–2031 (USD MILLION) 263
TABLE 341 LATIN AMERICA: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET FOR CROS, BY COUNTRY, 2024–2031 (USD MILLION) 264
TABLE 342 MIDDLE EAST: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET FOR CROS,
BY REGION, 2024–2031 (USD MILLION) 264
TABLE 343 GCC COUNTRIES: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET FOR CROS, BY COUNTRY, 2024–2031 (USD MILLION) 264
TABLE 344 IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2024–2031 (USD MILLION) 265
TABLE 345 NORTH AMERICA: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 266
TABLE 346 EUROPE: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 266
TABLE 347 ASIA PACIFIC: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 267
TABLE 348 LATIN AMERICA: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 267
TABLE 349 MIDDLE EAST: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2024–2031 (USD MILLION) 267
TABLE 350 GCC COUNTRIES: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 268
TABLE 351 IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET FOR FOOD & BEVERAGE COMPANIES, BY REGION, 2024–2031 (USD MILLION) 269
TABLE 352 NORTH AMERICA: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET FOR FOOD & BEVERAGE COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 269
TABLE 353 EUROPE: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET FOR FOOD & BEVERAGE COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 270
TABLE 354 ASIA PACIFIC: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET FOR FOOD & BEVERAGE COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 270
TABLE 355 LATIN AMERICA: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET FOR FOOD & BEVERAGE COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 271
TABLE 356 MIDDLE EAST: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET FOR FOOD & BEVERAGE COMPANIES, BY REGION, 2024–2031 (USD MILLION) 271
TABLE 357 GCC COUNTRIES: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET FOR FOOD & BEVERAGE COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 271
TABLE 358 IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET FOR OTHER END USERS, BY REGION, 2024–2031 (USD MILLION) 272
TABLE 359 NORTH AMERICA: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION) 273
TABLE 360 EUROPE: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION) 273
TABLE 361 ASIA PACIFIC: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION) 274
TABLE 362 LATIN AMERICA: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION) 274
TABLE 363 MIDDLE EAST: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET FOR OTHER END USERS, BY REGION, 2024–2031 (USD MILLION) 274
TABLE 364 GCC COUNTRIES: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION) 275
TABLE 365 IN VITRO TOXICOLOGY TESTING SERVICES MARKET, BY TYPE,
2024–2031 (USD MILLION) 277
TABLE 366 TOXICOLOGY TESTING SERVICES MARKET, BY REGION,
2024–2031 (USD MILLION) 277
TABLE 367 NORTH AMERICA: TOXICOLOGY TESTING SERVICES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 278
TABLE 368 EUROPE: TOXICOLOGY TESTING SERVICES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 278
TABLE 369 ASIA PACIFIC: TOXICOLOGY TESTING SERVICES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 279
TABLE 370 LATIN AMERICA: TOXICOLOGY TESTING SERVICES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 279
TABLE 371 MIDDLE EAST: TOXICOLOGY TESTING SERVICES MARKET, BY REGION,
2024–2031 (USD MILLION) 279
TABLE 372 GCC COUNTRIES: TOXICOLOGY TESTING SERVICES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 280
TABLE 373 TOXICOLOGY TESTING SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 280
TABLE 374 ORGAN-SPECIFIC TOXICITY SERVICES MARKET, BY REGION,
2024–2031 (USD MILLION) 281
TABLE 375 NORTH AMERICA: ORGAN-SPECIFIC TOXICITY SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 281
TABLE 376 EUROPE: ORGAN-SPECIFIC TOXICITY SERVICES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 281
TABLE 377 ASIA PACIFIC: ORGAN-SPECIFIC TOXICITY SERVICES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 282
TABLE 378 LATIN AMERICA: ORGAN-SPECIFIC TOXICITY SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 282
TABLE 379 MIDDLE EAST: ORGAN-SPECIFIC TOXICITY SERVICES MARKET, BY REGION,
2024–2031 (USD MILLION) 282
TABLE 380 GCC COUNTRIES: ORGAN-SPECIFIC TOXICITY SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 283
TABLE 381 CYTOTOXICITY TESTING SERVICES MARKET, BY REGION,
2024–2031 (USD MILLION) 283
TABLE 382 NORTH AMERICA: CYTOTOXICITY TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 284
TABLE 383 EUROPE: CYTOTOXICITY TESTING SERVICES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 284
TABLE 384 ASIA PACIFIC: CYTOTOXICITY TESTING SERVICES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 285
TABLE 385 LATIN AMERICA: CYTOTOXICITY TESTING SERVICES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 285
TABLE 386 MIDDLE EAST: CYTOTOXICITY TESTING SERVICES MARKET, BY REGION,
2024–2031 (USD MILLION) 285
TABLE 387 GCC COUNTRIES: CYTOTOXICITY TESTING SERVICES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 286
TABLE 388 GENOTOXICITY TESTING SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION) 286
TABLE 389 NORTH AMERICA: GENOTOXICITY TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 287
TABLE 390 EUROPE: GENOTOXICITY TESTING SERVICES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 287
TABLE 391 ASIA PACIFIC: GENOTOXICITY TESTING SERVICES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 288
TABLE 392 LATIN AMERICA: GENOTOXICITY TESTING SERVICES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 288
TABLE 393 MIDDLE EAST: GENOTOXICITY TESTING SERVICES MARKET, BY REGION,
2024–2031 (USD MILLION) 288
TABLE 394 GCC COUNTRIES: GENOTOXICITY TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 289
TABLE 395 OTHER TOXICITY TESTING SERVICES MARKET, BY REGION,
2024–2031 (USD MILLION) 289
TABLE 396 NORTH AMERICA: OTHER TOXICITY TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 290
TABLE 397 EUROPE: OTHER TOXICITY TESTING SERVICES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 290
TABLE 398 ASIA PACIFIC: OTHER TOXICITY TESTING SERVICES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 291
TABLE 399 LATIN AMERICA: OTHER TOXICITY TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 291
TABLE 400 MIDDLE EAST: OTHER TOXICITY TESTING SERVICES MARKET, BY REGION,
2024–2031 (USD MILLION) 291
TABLE 401 GCC COUNTRIES: OTHER TOXICITY TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 292
TABLE 402 BIOLOGICAL MODEL & ASSAY DEVELOPMENT SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION) 292
TABLE 403 NORTH AMERICA: BIOLOGICAL MODEL & ASSAY DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 293
TABLE 404 EUROPE: BIOLOGICAL MODEL & ASSAY DEVELOPMENT SERVICES MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 293
TABLE 405 ASIA PACIFIC: BIOLOGICAL MODEL & ASSAY DEVELOPMENT SERVICES MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 294
TABLE 406 LATIN AMERICA: BIOLOGICAL MODEL & ASSAY DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 294
TABLE 407 MIDDLE EAST: BIOLOGICAL MODEL & ASSAY DEVELOPMENT SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION) 294
TABLE 408 GCC COUNTRIES: BIOLOGICAL MODEL & ASSAY DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 295
TABLE 409 IMAGING & ANALYTICAL TOXICOLOGY SERVICES MARKET, BY REGION,
2024–2031 (USD MILLION) 295
TABLE 410 NORTH AMERICA: IMAGING & ANALYTICAL TOXICOLOGY SERVICES MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 296
TABLE 411 EUROPE: IMAGING & ANALYTICAL TOXICOLOGY SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 296
TABLE 412 ASIA PACIFIC: IMAGING & ANALYTICAL TOXICOLOGY SERVICES MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 297
TABLE 413 LATIN AMERICA: IMAGING & ANALYTICAL TOXICOLOGY SERVICES MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 297
TABLE 414 MIDDLE EAST: IMAGING & ANALYTICAL TOXICOLOGY SERVICES MARKET,
BY REGION, 2024–2031 (USD MILLION) 297
TABLE 415 GCC COUNTRIES: IMAGING & ANALYTICAL TOXICOLOGY SERVICES MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 298
TABLE 416 DATA ANALYSIS, BIOINFORMATICS, AND PREDICTIVE TOXICOLOGY MARKET,
BY REGION, 2024–2031 (USD MILLION) 298
TABLE 417 NORTH AMERICA: DATA ANALYSIS, BIOINFORMATICS, AND PREDICTIVE TOXICOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 299
TABLE 418 EUROPE: DATA ANALYSIS, BIOINFORMATICS, AND PREDICTIVE TOXICOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 299
TABLE 419 ASIA PACIFIC: DATA ANALYSIS, BIOINFORMATICS, AND PREDICTIVE TOXICOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 300
TABLE 420 LATIN AMERICA: DATA ANALYSIS, BIOINFORMATICS, AND PREDICTIVE TOXICOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 300
TABLE 421 MIDDLE EAST: DATA ANALYSIS, BIOINFORMATICS, AND PREDICTIVE TOXICOLOGY MARKET, BY REGION, 2024–2031 (USD MILLION) 300
TABLE 422 GCC COUNTRIES: DATA ANALYSIS, BIOINFORMATICS, AND PREDICTIVE TOXICOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 301
TABLE 423 IN VITRO TOXICOLOGY TESTING SERVICES MARKET, BY METHOD,
2024–2031 (USD MILLION) 303
TABLE 424 CELL-BASED TOXICITY TESTING SERVICES MARKET, BY REGION,
2024–2031 (USD MILLION) 304
TABLE 425 NORTH AMERICA: CELL-BASED TOXICITY TESTING SERVICES MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 304
TABLE 426 EUROPE: CELL-BASED TOXICITY TESTING SERVICES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 305
TABLE 427 ASIA PACIFIC: CELL-BASED TOXICITY TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 305
TABLE 428 LATIN AMERICA: CELL-BASED TOXICITY TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 306
TABLE 429 MIDDLE EAST: CELL-BASED TOXICITY TESTING SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION) 306
TABLE 430 GCC COUNTRIES: CELL-BASED TOXICITY TESTING SERVICES MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 306
TABLE 431 BIOCHEMICAL TOXICITY TESTING SERVICES MARKET, BY REGION,
2024–2031 (USD MILLION) 307
TABLE 432 NORTH AMERICA: BIOCHEMICAL TOXICITY TESTING SERVICES MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 308
TABLE 433 EUROPE: BIOCHEMICAL TOXICITY TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 308
TABLE 434 ASIA PACIFIC: BIOCHEMICAL TOXICITY TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 309
TABLE 435 LATIN AMERICA: BIOCHEMICAL TOXICITY TESTING SERVICES MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 309
TABLE 436 MIDDLE EAST: BIOCHEMICAL TOXICITY TESTING SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION) 309
TABLE 437 GCC COUNTRIES: BIOCHEMICAL TOXICITY TESTING SERVICES MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 310
TABLE 438 IN SILICO/COMPUTATIONAL TOXICITY TESTING SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION) 310
TABLE 439 NORTH AMERICA: IN SILICO/COMPUTATIONAL TOXICITY TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 311
TABLE 440 EUROPE: IN SILICO/COMPUTATIONAL TOXICITY TESTING SERVICES MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 311
TABLE 441 ASIA PACIFIC: IN SILICO/COMPUTATIONAL TOXICITY TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 312
TABLE 442 LATIN AMERICA: IN SILICO/COMPUTATIONAL TOXICITY TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 312
TABLE 443 MIDDLE EAST: IN SILICO/COMPUTATIONAL TOXICITY TESTING SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION) 312
TABLE 444 GCC COUNTRIES: IN SILICO/COMPUTATIONAL TOXICITY TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 313
TABLE 445 MOLECULAR & OMICS-BASED TOXICOLOGY SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION) 314
TABLE 446 NORTH AMERICA: MOLECULAR & OMICS-BASED TOXICOLOGY SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 314
TABLE 447 EUROPE: MOLECULAR & OMICS-BASED TOXICOLOGY SERVICES MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 315
TABLE 448 ASIA PACIFIC: MOLECULAR & OMICS-BASED TOXICOLOGY SERVICES MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 315
TABLE 449 LATIN AMERICA: MOLECULAR & OMICS-BASED TOXICOLOGY SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 316
TABLE 450 MIDDLE EAST: MOLECULAR & OMICS-BASED TOXICOLOGY SERVICES MARKET,
BY REGION, 2024–2031 (USD MILLION) 316
TABLE 451 GCC COUNTRIES: MOLECULAR & OMICS-BASED TOXICOLOGY SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 316
TABLE 452 EX VIVO MODEL-BASED TOXICITY TESTING SERVICES MARKET, BY REGION,
2024–2031 (USD MILLION) 317
TABLE 453 NORTH AMERICA: EX VIVO MODEL-BASED TOXICITY TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 317
TABLE 454 EUROPE: EX VIVO MODEL-BASED TOXICITY TESTING SERVICES MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 318
TABLE 455 ASIA PACIFIC: EX VIVO MODEL-BASED TOXICITY TESTING SERVICES MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 318
TABLE 456 LATIN AMERICA: EX VIVO MODEL-BASED TOXICITY TESTING SERVICES MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 319
TABLE 457 MIDDLE EAST: EX VIVO MODEL-BASED TOXICITY TESTING SERVICES MARKET,
BY REGION, 2024–2031 (USD MILLION) 319
TABLE 458 GCC COUNTRIES: EX VIVO MODEL-BASED TOXICITY TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 319
TABLE 459 OTHER IN VITRO TOXICOLOGY TESTING SERVICES MARKET, BY REGION,
2024–2031 (USD MILLION) 320
TABLE 460 NORTH AMERICA: OTHER IN VITRO TOXICOLOGY TESTING SERVICES MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 320
TABLE 461 EUROPE: OTHER IN VITRO TOXICOLOGY TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 321
TABLE 462 ASIA PACIFIC: OTHER IN VITRO TOXICOLOGY TESTING SERVICES MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 321
TABLE 463 LATIN AMERICA: OTHER IN VITRO TOXICOLOGY TESTING SERVICES MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 322
TABLE 464 MIDDLE EAST: OTHER IN VITRO TOXICOLOGY TESTING SERVICES MARKET,
BY REGION, 2024–2031 (USD MILLION) 322
TABLE 465 GCC COUNTRIES: OTHER IN VITRO TOXICOLOGY TESTING SERVICES MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 322
TABLE 466 IN VITRO TOXICOLOGY TESTING SERVICES MARKET, BY END USER,
2024–2031 (USD MILLION) 324
TABLE 467 IN VITRO TOXICOLOGY TESTING SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024–2031 (USD MILLION) 325
TABLE 468 NORTH AMERICA: IN VITRO TOXICOLOGY TESTING SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY,
2024–2031 (USD MILLION) 325
TABLE 469 EUROPE: IN VITRO TOXICOLOGY TESTING SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY,
2024–2031 (USD MILLION) 326
TABLE 470 ASIA PACIFIC: IN VITRO TOXICOLOGY TESTING SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY,
2024–2031 (USD MILLION) 326
TABLE 471 LATIN AMERICA: IN VITRO TOXICOLOGY TESTING SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY,
2024–2031 (USD MILLION) 327
TABLE 472 MIDDLE EAST: IN VITRO TOXICOLOGY TESTING SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION,
2024–2031 (USD MILLION) 327
TABLE 473 GCC COUNTRIES: IN VITRO TOXICOLOGY TESTING SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY,
2024–2031 (USD MILLION) 327
TABLE 474 IN VITRO TOXICOLOGY TESTING SERVICES MARKET FOR CONSUMER CARE COMPANIES, BY REGION, 2024–2031 (USD MILLION) 328
TABLE 475 NORTH AMERICA: IN VITRO TOXICOLOGY TESTING SERVICES MARKET FOR CONSUMER CARE COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 329
TABLE 476 EUROPE: IN VITRO TOXICOLOGY TESTING SERVICES MARKET FOR CONSUMER CARE COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 329
TABLE 477 ASIA PACIFIC: IN VITRO TOXICOLOGY TESTING SERVICES MARKET FOR CONSUMER CARE COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 330
TABLE 478 LATIN AMERICA: IN VITRO TOXICOLOGY TESTING SERVICES MARKET FOR CONSUMER CARE COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 330
TABLE 479 MIDDLE EAST: IN VITRO TOXICOLOGY TESTING SERVICES MARKET FOR CONSUMER CARE COMPANIES, BY REGION, 2024–2031 (USD MILLION) 330
TABLE 480 GCC COUNTRIES: IN VITRO TOXICOLOGY TESTING SERVICES MARKET FOR CONSUMER CARE COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 331
TABLE 481 IN VITRO TOXICOLOGY TESTING SERVICES MARKET FOR FOOD & BEVERAGE COMPANIES, BY REGION, 2024–2031 (USD MILLION) 332
TABLE 482 NORTH AMERICA: IN VITRO TOXICOLOGY TESTING SERVICES MARKET FOR FOOD & BEVERAGE COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 332
TABLE 483 EUROPE: IN VITRO TOXICOLOGY TESTING SERVICES MARKET FOR FOOD & BEVERAGE COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 333
TABLE 484 ASIA PACIFIC: IN VITRO TOXICOLOGY TESTING SERVICES MARKET FOR FOOD & BEVERAGE COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 333
TABLE 485 LATIN AMERICA: IN VITRO TOXICOLOGY TESTING SERVICES MARKET FOR FOOD & BEVERAGE COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 334
TABLE 486 MIDDLE EAST: IN VITRO TOXICOLOGY TESTING SERVICES MARKET FOR FOOD & BEVERAGE COMPANIES, BY REGION, 2024–2031 (USD MILLION) 334
TABLE 487 GCC COUNTRIES: IN VITRO TOXICOLOGY TESTING SERVICES MARKET FOR FOOD & BEVERAGE COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 334
TABLE 488 IN VITRO TOXICOLOGY TESTING SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2024–2031 (USD MILLION) 335
TABLE 489 NORTH AMERICA: IN VITRO TOXICOLOGY TESTING SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 336
TABLE 490 EUROPE: IN VITRO TOXICOLOGY TESTING SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 336
TABLE 491 ASIA PACIFIC: IN VITRO TOXICOLOGY TESTING SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 337
TABLE 492 LATIN AMERICA: IN VITRO TOXICOLOGY TESTING SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 337
TABLE 493 MIDDLE EAST: IN VITRO TOXICOLOGY TESTING SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2024–2031 (USD MILLION) 337
TABLE 494 GCC COUNTRIES: IN VITRO TOXICOLOGY TESTING SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 338
TABLE 495 IN VITRO TOXICOLOGY TESTING SERVICES MARKET FOR OTHER END USERS, BY REGION, 2024–2031 (USD MILLION) 339
TABLE 496 NORTH AMERICA: IN VITRO TOXICOLOGY TESTING SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION) 339
TABLE 497 EUROPE: IN VITRO TOXICOLOGY TESTING SERVICES MARKET FOR OTHER
END USERS, BY COUNTRY, 2024–2031 (USD MILLION) 340
TABLE 498 ASIA PACIFIC: IN VITRO TOXICOLOGY TESTING SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION) 340
TABLE 499 LATIN AMERICA: IN VITRO TOXICOLOGY TESTING SERVICES MARKET FOR
OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION) 341
TABLE 500 MIDDLE EAST: IN VITRO TOXICOLOGY TESTING SERVICES MARKET FOR
OTHER END USERS, BY REGION, 2024–2031 (USD MILLION) 341
TABLE 501 GCC COUNTRIES: IN VITRO TOXICOLOGY TESTING SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION) 341
TABLE 502 IN VITRO TOXICOLOGY TESTING MARKET, BY REGION, 2024–2031 (USD MILLION) 343
TABLE 503 NORTH AMERICA: IN VITRO TOXICOLOGY TESTING MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 344
TABLE 504 NORTH AMERICA: IN VITRO TOXICOLOGY TESTING MARKET, BY OFFERING,
2024–2031 (USD MILLION) 345
TABLE 505 NORTH AMERICA: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 345
TABLE 506 NORTH AMERICA: IN VITRO TOXICOLOGY TESTING REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 345
TABLE 507 NORTH AMERICA: IN VITRO TOXICOLOGY TESTING ASSAY KITS MARKET, BY TYPE, 2024–2031 (USD MILLION) 346
TABLE 508 NORTH AMERICA: IN VITRO TOXICOLOGY TESTING EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 346
TABLE 509 NORTH AMERICA: DETECTION, IMAGING, AND ANALYTICAL SYSTEMS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 346
TABLE 510 NORTH AMERICA: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET,
BY TOXICITY ENDPOINT & TEST, 2024–2031 (USD MILLION) 347
TABLE 511 NORTH AMERICA: ORGAN TOXICITY TESTING MARKET, BY TYPE,
2024–2031 (USD MILLION) 347
TABLE 512 NORTH AMERICA: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET,
BY TECHNOLOGY, 2024–2031 (USD MILLION) 348
TABLE 513 NORTH AMERICA: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET,
BY METHOD, 2024–2031 (USD MILLION) 348
TABLE 514 NORTH AMERICA: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET,
BY END USER, 2024–2031 (USD MILLION) 349
TABLE 515 NORTH AMERICA: IN VITRO TOXICOLOGY TESTING SERVICES MARKET,
BY TYPE, 2024–2031 (USD MILLION) 349
TABLE 516 NORTH AMERICA: TOXICOLOGY TESTING SERVICES MARKET, BY TYPE,
2024–2031 (USD MILLION) 350
TABLE 517 NORTH AMERICA: IN VITRO TOXICOLOGY TESTING SERVICES MARKET, BY METHOD, 2024–2031 (USD MILLION) 350
TABLE 518 NORTH AMERICA: IN VITRO TOXICOLOGY TESTING SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 351
TABLE 519 US: IN VITRO TOXICOLOGY TESTING MARKET, BY OFFERING, 2024–2031 (USD MILLION) 352
TABLE 520 US: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 352
TABLE 521 US: IN VITRO TOXICOLOGY TESTING REAGENTS & CONSUMABLES MARKET,
BY TYPE, 2024–2031 (USD MILLION) 353
TABLE 522 US: IN VITRO TOXICOLOGY TESTING ASSAY KITS MARKET, BY TYPE,
2024–2031 (USD MILLION) 353
TABLE 523 US: IN VITRO TOXICOLOGY TESTING EQUIPMENT MARKET, BY TYPE,
2024–2031 (USD MILLION) 354
TABLE 524 US: DETECTION, IMAGING, AND ANALYTICAL SYSTEMS MARKET, BY TYPE,
2024–2031 (USD MILLION) 354
TABLE 525 US: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY TOXICITY ENDPOINT & TEST, 2024–2031 (USD MILLION) 355
TABLE 526 US: ORGAN TOXICITY TESTING MARKET, BY TYPE, 2024–2031 (USD MILLION) 355
TABLE 527 US: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 356
TABLE 528 US: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY METHOD,
2024–2031 (USD MILLION) 356
TABLE 529 US: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY END USER,
2024–2031 (USD MILLION) 357
TABLE 530 US: IN VITRO TOXICOLOGY TESTING SERVICES MARKET, BY TYPE,
2024–2031 (USD MILLION) 357
TABLE 531 US: TOXICOLOGY TESTING SERVICES MARKET, BY TYPE,
2024–2031 (USD MILLION) 358
TABLE 532 US: IN VITRO TOXICOLOGY TESTING SERVICES MARKET, BY METHOD,
2024–2031 (USD MILLION) 358
TABLE 533 US: IN VITRO TOXICOLOGY TESTING SERVICES MARKET, BY END USER,
2024–2031 (USD MILLION) 359
TABLE 534 CANADA: IN VITRO TOXICOLOGY TESTING MARKET, BY OFFERING,
2024–2031 (USD MILLION) 360
TABLE 535 CANADA: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 360
TABLE 536 CANADA: IN VITRO TOXICOLOGY TESTING REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 360
TABLE 537 CANADA: IN VITRO TOXICOLOGY TESTING ASSAY KITS MARKET, BY TYPE,
2024–2031 (USD MILLION) 361
TABLE 538 CANADA: IN VITRO TOXICOLOGY TESTING EQUIPMENT MARKET, BY TYPE,
2024–2031 (USD MILLION) 361
TABLE 539 CANADA: DETECTION, IMAGING, AND ANALYTICAL SYSTEMS MARKET, BY TYPE, 2024–2031 (USD MILLION) 362
TABLE 540 CANADA: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY TOXICITY ENDPOINT & TEST, 2024–2031 (USD MILLION) 362
TABLE 541 CANADA: ORGAN TOXICITY TESTING MARKET, BY TYPE, 2024–2031 (USD MILLION) 363
TABLE 542 CANADA: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 363
TABLE 543 CANADA: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY METHOD,
2024–2031 (USD MILLION) 364
TABLE 544 CANADA: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION) 364
TABLE 545 CANADA: IN VITRO TOXICOLOGY TESTING SERVICES MARKET, BY TYPE,
2024–2031 (USD MILLION) 365
TABLE 546 CANADA: TOXICOLOGY TESTING SERVICES MARKET, BY TYPE,
2024–2031 (USD MILLION) 365
TABLE 547 CANADA: IN VITRO TOXICOLOGY TESTING SERVICES MARKET, BY METHOD,
2024–2031 (USD MILLION) 366
TABLE 548 CANADA: IN VITRO TOXICOLOGY TESTING SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 366
TABLE 549 EUROPE: IN VITRO TOXICOLOGY TESTING MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 367
TABLE 550 EUROPE: IN VITRO TOXICOLOGY TESTING MARKET, BY OFFERING,
2024–2031 (USD MILLION) 367
TABLE 551 EUROPE: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 368
TABLE 552 EUROPE: IN VITRO TOXICOLOGY TESTING REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 368
TABLE 553 EUROPE: IN VITRO TOXICOLOGY TESTING ASSAY KITS MARKET, BY TYPE,
2024–2031 (USD MILLION) 369
TABLE 554 EUROPE: IN VITRO TOXICOLOGY TESTING EQUIPMENT MARKET, BY TYPE,
2024–2031 (USD MILLION) 369
TABLE 555 EUROPE: DETECTION, IMAGING, AND ANALYTICAL SYSTEMS MARKET, BY TYPE, 2024–2031 (USD MILLION) 369
TABLE 556 EUROPE: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY TOXICITY ENDPOINT & TEST, 2024–2031 (USD MILLION) 370
TABLE 557 EUROPE: ORGAN TOXICITY TESTING MARKET, BY TYPE, 2024–2031 (USD MILLION) 370
TABLE 558 EUROPE: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 371
TABLE 559 EUROPE: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY METHOD, 2024–2031 (USD MILLION) 371
TABLE 560 EUROPE: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION) 372
TABLE 561 EUROPE: IN VITRO TOXICOLOGY TESTING SERVICES MARKET, BY TYPE
, 2024–2031 (USD MILLION) 372
TABLE 562 EUROPE: TOXICOLOGY TESTING SERVICES MARKET, BY TYPE,
2024–2031 (USD MILLION) 373
TABLE 563 EUROPE: IN VITRO TOXICOLOGY TESTING SERVICES MARKET, BY METHOD,
2024–2031 (USD MILLION) 373
TABLE 564 EUROPE: IN VITRO TOXICOLOGY TESTING SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 374
TABLE 565 GERMANY: IN VITRO TOXICOLOGY TESTING MARKET, BY OFFERING,
2024–2031 (USD MILLION) 375
TABLE 566 GERMANY: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 375
TABLE 567 GERMANY: IN VITRO TOXICOLOGY TESTING REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 376
TABLE 568 GERMANY: IN VITRO TOXICOLOGY TESTING ASSAY KITS MARKET, BY TYPE,
2024–2031 (USD MILLION) 376
TABLE 569 GERMANY: IN VITRO TOXICOLOGY TESTING EQUIPMENT MARKET, BY TYPE,
2024–2031 (USD MILLION) 377
TABLE 570 GERMANY: DETECTION, IMAGING, AND ANALYTICAL SYSTEMS MARKET, BY TYPE, 2024–2031 (USD MILLION) 377
TABLE 571 GERMANY: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY TOXICITY ENDPOINT & TEST, 2024–2031 (USD MILLION) 378
TABLE 572 GERMANY: ORGAN TOXICITY TESTING MARKET, BY TYPE,
2024–2031 (USD MILLION) 378
TABLE 573 GERMANY: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 379
TABLE 574 GERMANY: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY METHOD, 2024–2031 (USD MILLION) 379
TABLE 575 GERMANY: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION) 380
TABLE 576 GERMANY: IN VITRO TOXICOLOGY TESTING SERVICES MARKET, BY TYPE,
2024–2031 (USD MILLION) 380
TABLE 577 GERMANY: TOXICOLOGY TESTING SERVICES MARKET, BY TYPE,
2024–2031 (USD MILLION) 381
TABLE 578 GERMANY: IN VITRO TOXICOLOGY TESTING SERVICES MARKET, BY METHOD, 2024–2031 (USD MILLION) 381
TABLE 579 GERMANY: IN VITRO TOXICOLOGY TESTING SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 382
TABLE 580 UK: IN VITRO TOXICOLOGY TESTING MARKET, BY OFFERING,
2024–2031 (USD MILLION) 383
TABLE 581 UK: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 383
TABLE 582 UK: IN VITRO TOXICOLOGY TESTING REAGENTS & CONSUMABLES MARKET,
BY TYPE, 2024–2031 (USD MILLION) 384
TABLE 583 UK: IN VITRO TOXICOLOGY TESTING ASSAY KITS MARKET, BY TYPE,
2024–2031 (USD MILLION) 384
TABLE 584 UK: IN VITRO TOXICOLOGY TESTING EQUIPMENT MARKET, BY TYPE,
2024–2031 (USD MILLION) 385
TABLE 585 UK: DETECTION, IMAGING, AND ANALYTICAL SYSTEMS MARKET, BY TYPE,
2024–2031 (USD MILLION) 385
TABLE 586 UK: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY TOXICITY ENDPOINT & TEST, 2024–2031 (USD MILLION) 386
TABLE 587 UK: ORGAN TOXICITY TESTING MARKET, BY TYPE, 2024–2031 (USD MILLION) 386
TABLE 588 UK: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 387
TABLE 589 UK: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY METHOD,
2024–2031 (USD MILLION) 387
TABLE 590 UK: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY END USER,
2024–2031 (USD MILLION) 388
TABLE 591 UK: IN VITRO TOXICOLOGY TESTING SERVICES MARKET, BY TYPE,
2024–2031 (USD MILLION) 388
TABLE 592 UK: TOXICOLOGY TESTING SERVICES MARKET, BY TYPE,
2024–2031 (USD MILLION) 389
TABLE 593 UK: IN VITRO TOXICOLOGY TESTING SERVICES MARKET, BY METHOD,
2024–2031 (USD MILLION) 389
TABLE 594 UK: IN VITRO TOXICOLOGY TESTING SERVICES MARKET, BY END USER,
2024–2031 (USD MILLION) 390
TABLE 595 FRANCE: IN VITRO TOXICOLOGY TESTING MARKET, BY OFFERING,
2024–2031 (USD MILLION) 391
TABLE 596 FRANCE: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 391
TABLE 597 FRANCE: IN VITRO TOXICOLOGY TESTING REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 392
TABLE 598 FRANCE: IN VITRO TOXICOLOGY TESTING ASSAY KITS MARKET, BY TYPE,
2024–2031 (USD MILLION) 392
TABLE 599 FRANCE: IN VITRO TOXICOLOGY TESTING EQUIPMENT MARKET, BY TYPE,
2024–2031 (USD MILLION) 393
TABLE 600 FRANCE: DETECTION, IMAGING, AND ANALYTICAL SYSTEMS MARKET, BY TYPE, 2024–2031 (USD MILLION) 393
TABLE 601 FRANCE: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY TOXICITY ENDPOINT & TEST, 2024–2031 (USD MILLION) 394
TABLE 602 FRANCE: ORGAN TOXICITY TESTING MARKET, BY TYPE, 2024–2031 (USD MILLION) 394
TABLE 603 FRANCE: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 395
TABLE 604 FRANCE: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY METHOD,
2024–2031 (USD MILLION) 395
TABLE 605 FRANCE: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION) 396
TABLE 606 FRANCE: IN VITRO TOXICOLOGY TESTING SERVICES MARKET, BY TYPE,
2024–2031 (USD MILLION) 396
TABLE 607 FRANCE: TOXICOLOGY TESTING SERVICES MARKET, BY TYPE,
2024–2031 (USD MILLION) 397
TABLE 608 FRANCE: IN VITRO TOXICOLOGY TESTING SERVICES MARKET, BY METHOD,
2024–2031 (USD MILLION) 397
TABLE 609 FRANCE: IN VITRO TOXICOLOGY TESTING SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 398
TABLE 610 ITALY: IN VITRO TOXICOLOGY TESTING MARKET, BY OFFERING,
2024–2031 (USD MILLION) 398
TABLE 611 ITALY: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 399
TABLE 612 ITALY: IN VITRO TOXICOLOGY TESTING REAGENTS & CONSUMABLES MARKET,
BY TYPE, 2024–2031 (USD MILLION) 399
TABLE 613 ITALY: IN VITRO TOXICOLOGY TESTING ASSAY KITS MARKET, BY TYPE
, 2024–2031 (USD MILLION) 400
TABLE 614 ITALY: IN VITRO TOXICOLOGY TESTING EQUIPMENT MARKET, BY TYPE,
2024–2031 (USD MILLION) 400
TABLE 615 ITALY: DETECTION, IMAGING, AND ANALYTICAL SYSTEMS MARKET, BY TYPE, 2024–2031 (USD MILLION) 400
TABLE 616 ITALY: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY TOXICITY ENDPOINT & TEST, 2024–2031 (USD MILLION) 401
TABLE 617 ITALY: ORGAN TOXICITY TESTING MARKET, BY TYPE, 2024–2031 (USD MILLION) 401
TABLE 618 ITALY: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 402
TABLE 619 ITALY: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY METHOD,
2024–2031 (USD MILLION) 402
TABLE 620 ITALY: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY END USER,
2024–2031 (USD MILLION) 403
TABLE 621 ITALY: IN VITRO TOXICOLOGY TESTING SERVICES MARKET, BY TYPE,
2024–2031 (USD MILLION) 403
TABLE 622 ITALY: TOXICOLOGY TESTING SERVICES MARKET, BY TYPE,
2024–2031 (USD MILLION) 404
TABLE 623 ITALY: IN VITRO TOXICOLOGY TESTING SERVICES MARKET, BY METHOD,
2024–2031 (USD MILLION) 404
TABLE 624 ITALY: IN VITRO TOXICOLOGY TESTING SERVICES MARKET, BY END USER,
2024–2031 (USD MILLION) 405
TABLE 625 SPAIN: IN VITRO TOXICOLOGY TESTING MARKET, BY OFFERING,
2024–2031 (USD MILLION) 406
TABLE 626 SPAIN: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 406
TABLE 627 SPAIN: IN VITRO TOXICOLOGY TESTING REAGENTS & CONSUMABLES MARKET,
BY TYPE, 2024–2031 (USD MILLION) 406
TABLE 628 SPAIN: IN VITRO TOXICOLOGY TESTING ASSAY KITS MARKET, BY TYPE,
2024–2031 (USD MILLION) 407
TABLE 629 SPAIN: IN VITRO TOXICOLOGY TESTING EQUIPMENT MARKET, BY TYPE,
2024–2031 (USD MILLION) 407
TABLE 630 SPAIN: DETECTION, IMAGING, AND ANALYTICAL SYSTEMS MARKET, BY TYPE, 2024–2031 (USD MILLION) 408
TABLE 631 SPAIN: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY TOXICITY ENDPOINT & TEST, 2024–2031 (USD MILLION) 408
TABLE 632 SPAIN: ORGAN TOXICITY TESTING MARKET, BY TYPE, 2024–2031 (USD MILLION) 409
TABLE 633 SPAIN: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 409
TABLE 634 SPAIN: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY METHOD,
2024–2031 (USD MILLION) 410
TABLE 635 SPAIN: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY END USER,
2024–2031 (USD MILLION) 410
TABLE 636 SPAIN: IN VITRO TOXICOLOGY TESTING SERVICES MARKET, BY TYPE,
2024–2031 (USD MILLION) 411
TABLE 637 SPAIN: TOXICOLOGY TESTING SERVICES MARKET, BY TYPE,
2024–2031 (USD MILLION) 411
TABLE 638 SPAIN: IN VITRO TOXICOLOGY TESTING SERVICES MARKET, BY METHOD,
2024–2031 (USD MILLION) 412
TABLE 639 SPAIN: IN VITRO TOXICOLOGY TESTING SERVICES MARKET, BY END USER,
2024–2031 (USD MILLION) 412
TABLE 640 REST OF EUROPE: IN VITRO TOXICOLOGY TESTING MARKET, BY OFFERING,
2024–2031 (USD MILLION) 413
TABLE 641 REST OF EUROPE: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 414
TABLE 642 REST OF EUROPE: IN VITRO TOXICOLOGY TESTING REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 414
TABLE 643 REST OF EUROPE: IN VITRO TOXICOLOGY TESTING ASSAY KITS MARKET, BY TYPE, 2024–2031 (USD MILLION) 415
TABLE 644 REST OF EUROPE: IN VITRO TOXICOLOGY TESTING EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 415
TABLE 645 REST OF EUROPE: DETECTION, IMAGING, AND ANALYTICAL SYSTEMS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 415
TABLE 646 REST OF EUROPE: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET,
BY TOXICITY ENDPOINT & TEST, 2024–2031 (USD MILLION) 416
TABLE 647 REST OF EUROPE: ORGAN TOXICITY TESTING MARKET, BY TYPE,
2024–2031 (USD MILLION) 416
TABLE 648 REST OF EUROPE: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET,
BY TECHNOLOGY, 2024–2031 (USD MILLION) 417
TABLE 649 REST OF EUROPE: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET,
BY METHOD, 2024–2031 (USD MILLION) 417
TABLE 650 REST OF EUROPE: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET,
BY END USER, 2024–2031 (USD MILLION) 418
TABLE 651 REST OF EUROPE: IN VITRO TOXICOLOGY TESTING SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 418
TABLE 652 REST OF EUROPE: TOXICOLOGY TESTING SERVICES MARKET, BY TYPE,
2024–2031 (USD MILLION) 419
TABLE 653 REST OF EUROPE: IN VITRO TOXICOLOGY TESTING SERVICES MARKET,
BY METHOD, 2024–2031 (USD MILLION) 419
TABLE 654 REST OF EUROPE: IN VITRO TOXICOLOGY TESTING SERVICES MARKET,
BY END USER, 2024–2031 (USD MILLION) 420
TABLE 655 ASIA PACIFIC: IN VITRO TOXICOLOGY TESTING MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 422
TABLE 656 ASIA PACIFIC: IN VITRO TOXICOLOGY TESTING MARKET, BY OFFERING,
2024–2031 (USD MILLION) 422
TABLE 657 ASIA PACIFIC: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 422
TABLE 658 ASIA PACIFIC: IN VITRO TOXICOLOGY TESTING REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 423
TABLE 659 ASIA PACIFIC: IN VITRO TOXICOLOGY TESTING ASSAY KITS MARKET, BY TYPE, 2024–2031 (USD MILLION) 423
TABLE 660 ASIA PACIFIC: IN VITRO TOXICOLOGY TESTING EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 423
TABLE 661 ASIA PACIFIC: DETECTION, IMAGING, AND ANALYTICAL SYSTEMS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 424
TABLE 662 ASIA PACIFIC: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY TOXICITY ENDPOINT & TEST, 2024–2031 (USD MILLION) 424
TABLE 663 ASIA PACIFIC: ORGAN TOXICITY TESTING MARKET, BY TYPE,
2024–2031 (USD MILLION) 425
TABLE 664 ASIA PACIFIC: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 425
TABLE 665 ASIA PACIFIC: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY METHOD, 2024–2031 (USD MILLION) 426
TABLE 666 ASIA PACIFIC: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION) 426
TABLE 667 ASIA PACIFIC: IN VITRO TOXICOLOGY TESTING SERVICES MARKET, BY TYPE,
2024–2031 (USD MILLION) 427
TABLE 668 ASIA PACIFIC: TOXICOLOGY TESTING SERVICES MARKET, BY TYPE,
2024–2031 (USD MILLION) 427
TABLE 669 ASIA PACIFIC: IN VITRO TOXICOLOGY TESTING SERVICES MARKET, BY METHOD, 2024–2031 (USD MILLION) 428
TABLE 670 ASIA PACIFIC: IN VITRO TOXICOLOGY TESTING SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 428
TABLE 671 CHINA: IN VITRO TOXICOLOGY TESTING MARKET, BY OFFERING,
2024–2031 (USD MILLION) 429
TABLE 672 CHINA: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 430
TABLE 673 CHINA: IN VITRO TOXICOLOGY TESTING REAGENTS & CONSUMABLES MARKET,
BY TYPE, 2024–2031 (USD MILLION) 430
TABLE 674 CHINA: IN VITRO TOXICOLOGY TESTING ASSAY KITS MARKET, BY TYPE,
2024–2031 (USD MILLION) 430
TABLE 675 CHINA: IN VITRO TOXICOLOGY TESTING EQUIPMENT MARKET, BY TYPE,
2024–2031 (USD MILLION) 431
TABLE 676 CHINA: DETECTION, IMAGING, AND ANALYTICAL SYSTEMS MARKET, BY TYPE, 2024–2031 (USD MILLION) 431
TABLE 677 CHINA: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY TOXICITY ENDPOINT & TEST, 2024–2031 (USD MILLION) 431
TABLE 678 CHINA: ORGAN TOXICITY TESTING MARKET, BY TYPE, 2024–2031 (USD MILLION) 432
TABLE 679 CHINA: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 432
TABLE 680 CHINA: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY METHOD,
2024–2031 (USD MILLION) 433
TABLE 681 CHINA: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY END USER,
2024–2031 (USD MILLION) 433
TABLE 682 CHINA: IN VITRO TOXICOLOGY TESTING SERVICES MARKET, BY TYPE,
2024–2031 (USD MILLION) 434
TABLE 683 CHINA: TOXICOLOGY TESTING SERVICES MARKET, BY TYPE,
2024–2031 (USD MILLION) 434
TABLE 684 CHINA: IN VITRO TOXICOLOGY TESTING SERVICES MARKET, BY METHOD,
2024–2031 (USD MILLION) 435
TABLE 685 CHINA: IN VITRO TOXICOLOGY TESTING SERVICES MARKET, BY END USER,
2024–2031 (USD MILLION) 435
TABLE 686 JAPAN: IN VITRO TOXICOLOGY TESTING MARKET, BY OFFERING,
2024–2031 (USD MILLION) 437
TABLE 687 JAPAN: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 437
TABLE 688 JAPAN: IN VITRO TOXICOLOGY TESTING REAGENTS & CONSUMABLES MARKET,
BY TYPE, 2024–2031 (USD MILLION) 437
TABLE 689 JAPAN: IN VITRO TOXICOLOGY TESTING ASSAY KITS MARKET, BY TYPE,
2024–2031 (USD MILLION) 438
TABLE 690 JAPAN: IN VITRO TOXICOLOGY TESTING EQUIPMENT MARKET, BY TYPE,
2024–2031 (USD MILLION) 438
TABLE 691 JAPAN: DETECTION, IMAGING, AND ANALYTICAL SYSTEMS MARKET, BY TYPE, 2024–2031 (USD MILLION) 438
TABLE 692 JAPAN: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY TOXICITY ENDPOINT & TEST, 2024–2031 (USD MILLION) 439
TABLE 693 JAPAN: ORGAN TOXICITY TESTING MARKET, BY TYPE, 2024–2031 (USD MILLION) 439
TABLE 694 JAPAN: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 440
TABLE 695 JAPAN: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY METHOD,
2024–2031 (USD MILLION) 440
TABLE 696 JAPAN: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY END USER,
2024–2031 (USD MILLION) 441
TABLE 697 JAPAN: IN VITRO TOXICOLOGY TESTING SERVICES MARKET, BY TYPE,
2024–2031 (USD MILLION) 441
TABLE 698 JAPAN: TOXICOLOGY TESTING SERVICES MARKET, BY TYPE,
2024–2031 (USD MILLION) 442
TABLE 699 JAPAN: IN VITRO TOXICOLOGY TESTING SERVICES MARKET, BY METHOD,
2024–2031 (USD MILLION) 442
TABLE 700 JAPAN: IN VITRO TOXICOLOGY TESTING SERVICES MARKET, BY END USER,
2024–2031 (USD MILLION) 443
TABLE 701 INDIA: IN VITRO TOXICOLOGY TESTING MARKET, BY OFFERING,
2024–2031 (USD MILLION) 444
TABLE 702 INDIA: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 444
TABLE 703 INDIA: IN VITRO TOXICOLOGY TESTING REAGENTS & CONSUMABLES MARKET,
BY TYPE, 2024–2031 (USD MILLION) 445
TABLE 704 INDIA: IN VITRO TOXICOLOGY TESTING ASSAY KITS MARKET, BY TYPE,
2024–2031 (USD MILLION) 445
TABLE 705 INDIA: IN VITRO TOXICOLOGY TESTING EQUIPMENT MARKET, BY TYPE,
2024–2031 (USD MILLION) 445
TABLE 706 INDIA: DETECTION, IMAGING, AND ANALYTICAL SYSTEMS MARKET, BY TYPE, 2024–2031 (USD MILLION) 446
TABLE 707 INDIA: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY TOXICITY ENDPOINT & TEST, 2024–2031 (USD MILLION) 446
TABLE 708 INDIA: ORGAN TOXICITY TESTING MARKET, BY TYPE, 2024–2031 (USD MILLION) 447
TABLE 709 INDIA: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 447
TABLE 710 INDIA: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY METHOD,
2024–2031 (USD MILLION) 448
TABLE 711 INDIA: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY END USER,
2024–2031 (USD MILLION) 448
TABLE 712 INDIA: IN VITRO TOXICOLOGY TESTING SERVICES MARKET, BY TYPE,
2024–2031 (USD MILLION) 449
TABLE 713 INDIA: TOXICOLOGY TESTING SERVICES MARKET, BY TYPE,
2024–2031 (USD MILLION) 449
TABLE 714 INDIA: IN VITRO TOXICOLOGY TESTING SERVICES MARKET, BY METHOD,
2024–2031 (USD MILLION) 450
TABLE 715 INDIA: IN VITRO TOXICOLOGY TESTING SERVICES MARKET, BY END USER,
2024–2031 (USD MILLION) 450
TABLE 716 SOUTH KOREA: IN VITRO TOXICOLOGY TESTING MARKET, BY OFFERING,
2024–2031 (USD MILLION) 451
TABLE 717 SOUTH KOREA: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 452
TABLE 718 SOUTH KOREA: IN VITRO TOXICOLOGY TESTING REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 452
TABLE 719 SOUTH KOREA: IN VITRO TOXICOLOGY TESTING ASSAY KITS MARKET, BY TYPE, 2024–2031 (USD MILLION) 452
TABLE 720 SOUTH KOREA: IN VITRO TOXICOLOGY TESTING EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 453
TABLE 721 SOUTH KOREA: DETECTION, IMAGING, AND ANALYTICAL SYSTEMS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 453
TABLE 722 SOUTH KOREA: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET,
BY TOXICITY ENDPOINT & TEST, 2024–2031 (USD MILLION) 453
TABLE 723 SOUTH KOREA: ORGAN TOXICITY TESTING MARKET, BY TYPE,
2024–2031 (USD MILLION) 454
TABLE 724 SOUTH KOREA: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET,
BY TECHNOLOGY, 2024–2031 (USD MILLION) 454
TABLE 725 SOUTH KOREA: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET,
BY METHOD, 2024–2031 (USD MILLION) 455
TABLE 726 SOUTH KOREA: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET,
BY END USER, 2024–2031 (USD MILLION) 455
TABLE 727 SOUTH KOREA: IN VITRO TOXICOLOGY TESTING SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 456
TABLE 728 SOUTH KOREA: TOXICOLOGY TESTING SERVICES MARKET, BY TYPE,
2024–2031 (USD MILLION) 456
TABLE 729 SOUTH KOREA: IN VITRO TOXICOLOGY TESTING SERVICES MARKET, BY METHOD, 2024–2031 (USD MILLION) 457
TABLE 730 SOUTH KOREA: IN VITRO TOXICOLOGY TESTING SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 457
TABLE 731 AUSTRALIA: IN VITRO TOXICOLOGY TESTING MARKET, BY OFFERING,
2024–2031 (USD MILLION) 458
TABLE 732 AUSTRALIA: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 458
TABLE 733 AUSTRALIA: IN VITRO TOXICOLOGY TESTING REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 459
TABLE 734 AUSTRALIA: IN VITRO TOXICOLOGY TESTING ASSAY KITS MARKET, BY TYPE,
2024–2031 (USD MILLION) 459
TABLE 735 AUSTRALIA: IN VITRO TOXICOLOGY TESTING EQUIPMENT MARKET, BY TYPE,
2024–2031 (USD MILLION) 459
TABLE 736 AUSTRALIA: DETECTION, IMAGING, AND ANALYTICAL SYSTEMS MARKET, BY TYPE, 2024–2031 (USD MILLION) 460
TABLE 737 AUSTRALIA: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY TOXICITY ENDPOINT & TEST, 2024–2031 (USD MILLION) 460
TABLE 738 AUSTRALIA: ORGAN TOXICITY TESTING MARKET, BY TYPE,
2024–2031 (USD MILLION) 460
TABLE 739 AUSTRALIA: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 461
TABLE 740 AUSTRALIA: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY METHOD, 2024–2031 (USD MILLION) 461
TABLE 741 AUSTRALIA: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION) 462
TABLE 742 AUSTRALIA: IN VITRO TOXICOLOGY TESTING SERVICES MARKET, BY TYPE,
2024–2031 (USD MILLION) 462
TABLE 743 AUSTRALIA: TOXICOLOGY TESTING SERVICES MARKET, BY TYPE,
2024–2031 (USD MILLION) 463
TABLE 744 AUSTRALIA: IN VITRO TOXICOLOGY TESTING SERVICES MARKET, BY METHOD, 2024–2031 (USD MILLION) 463
TABLE 745 AUSTRALIA: IN VITRO TOXICOLOGY TESTING SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 464
TABLE 746 REST OF ASIA PACIFIC: IN VITRO TOXICOLOGY TESTING MARKET, BY OFFERING, 2024–2031 (USD MILLION) 465
TABLE 747 REST OF ASIA PACIFIC: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 465
TABLE 748 REST OF ASIA PACIFIC: IN VITRO TOXICOLOGY TESTING REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 465
TABLE 749 REST OF ASIA PACIFIC: IN VITRO TOXICOLOGY TESTING ASSAY KITS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 466
TABLE 750 REST OF ASIA PACIFIC: IN VITRO TOXICOLOGY TESTING EQUIPMENT MARKET,
BY TYPE, 2024–2031 (USD MILLION) 466
TABLE 751 REST OF ASIA PACIFIC: DETECTION, IMAGING, AND ANALYTICAL SYSTEMS MARKET, BY TYPE, 2024–2031 (USD MILLION) 466
TABLE 752 REST OF ASIA PACIFIC: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET,
BY TOXICITY ENDPOINT & TEST, 2024–2031 (USD MILLION) 467
TABLE 753 REST OF ASIA PACIFIC: ORGAN TOXICITY TESTING MARKET, BY TYPE,
2024–2031 (USD MILLION) 467
TABLE 754 REST OF ASIA PACIFIC: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET,
BY TECHNOLOGY, 2024–2031 (USD MILLION) 468
TABLE 755 REST OF ASIA PACIFIC: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET,
BY METHOD, 2024–2031 (USD MILLION) 468
TABLE 756 REST OF ASIA PACIFIC: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET,
BY END USER, 2024–2031 (USD MILLION) 469
TABLE 757 REST OF ASIA PACIFIC: IN VITRO TOXICOLOGY TESTING SERVICES MARKET,
BY TYPE, 2024–2031 (USD MILLION) 469
TABLE 758 REST OF ASIA PACIFIC: TOXICOLOGY TESTING SERVICES MARKET, BY TYPE,
2024–2031 (USD MILLION) 470
TABLE 759 REST OF ASIA PACIFIC: IN VITRO TOXICOLOGY TESTING SERVICES MARKET,
BY METHOD, 2024–2031 (USD MILLION) 470
TABLE 760 REST OF ASIA PACIFIC: IN VITRO TOXICOLOGY TESTING SERVICES MARKET,
BY END USER, 2024–2031 (USD MILLION) 471
TABLE 761 LATIN AMERICA: IN VITRO TOXICOLOGY TESTING MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 472
TABLE 762 LATIN AMERICA: IN VITRO TOXICOLOGY TESTING MARKET, BY OFFERING,
2024–2031 (USD MILLION) 472
TABLE 763 LATIN AMERICA: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 472
TABLE 764 LATIN AMERICA: IN VITRO TOXICOLOGY TESTING REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 473
TABLE 765 LATIN AMERICA: IN VITRO TOXICOLOGY TESTING ASSAY KITS MARKET, BY TYPE, 2024–2031 (USD MILLION) 473
TABLE 766 LATIN AMERICA: IN VITRO TOXICOLOGY TESTING EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 473
TABLE 767 LATIN AMERICA: DETECTION, IMAGING, AND ANALYTICAL SYSTEMS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 474
TABLE 768 LATIN AMERICA: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET,
BY TOXICITY ENDPOINT & TEST, 2024–2031 (USD MILLION) 474
TABLE 769 LATIN AMERICA: ORGAN TOXICITY TESTING MARKET, BY TYPE,
2024–2031 (USD MILLION) 475
TABLE 770 LATIN AMERICA: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET,
BY TECHNOLOGY, 2024–2031 (USD MILLION) 475
TABLE 771 LATIN AMERICA: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY METHOD, 2024–2031 (USD MILLION) 476
TABLE 772 LATIN AMERICA: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION) 476
TABLE 773 LATIN AMERICA: IN VITRO TOXICOLOGY TESTING SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 477
TABLE 774 LATIN AMERICA: TOXICOLOGY TESTING SERVICES MARKET, BY TYPE,
2024–2031 (USD MILLION) 477
TABLE 775 LATIN AMERICA: IN VITRO TOXICOLOGY TESTING SERVICES MARKET, BY METHOD, 2024–2031 (USD MILLION) 478
TABLE 776 LATIN AMERICA: IN VITRO TOXICOLOGY TESTING SERVICES MARKET,
BY END USER, 2024–2031 (USD MILLION) 478
TABLE 777 BRAZIL: IN VITRO TOXICOLOGY TESTING MARKET, BY OFFERING,
2024–2031 (USD MILLION) 479
TABLE 778 BRAZIL: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 479
TABLE 779 BRAZIL: IN VITRO TOXICOLOGY TESTING REAGENTS & CONSUMABLES MARKET,
BY TYPE, 2024–2031 (USD MILLION) 480
TABLE 780 BRAZIL: IN VITRO TOXICOLOGY TESTING ASSAY KITS MARKET, BY TYPE,
2024–2031 (USD MILLION) 480
TABLE 781 BRAZIL: IN VITRO TOXICOLOGY TESTING EQUIPMENT MARKET, BY TYPE
, 2024–2031 (USD MILLION) 480
TABLE 782 BRAZIL: DETECTION, IMAGING, AND ANALYTICAL SYSTEMS MARKET, BY TYPE, 2024–2031 (USD MILLION) 481
TABLE 783 BRAZIL: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY TOXICITY ENDPOINT & TEST, 2024–2031 (USD MILLION) 481
TABLE 784 BRAZIL: ORGAN TOXICITY TESTING MARKET, BY TYPE, 2024–2031 (USD MILLION) 482
TABLE 785 BRAZIL: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 482
TABLE 786 BRAZIL: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY METHOD,
2024–2031 (USD MILLION) 483
TABLE 787 BRAZIL: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION) 483
TABLE 788 BRAZIL: IN VITRO TOXICOLOGY TESTING SERVICES MARKET, BY TYPE,
2024–2031 (USD MILLION) 484
TABLE 789 BRAZIL: TOXICOLOGY TESTING SERVICES MARKET, BY TYPE,
2024–2031 (USD MILLION) 484
TABLE 790 BRAZIL: IN VITRO TOXICOLOGY TESTING SERVICES MARKET, BY METHOD,
2024–2031 (USD MILLION) 485
TABLE 791 BRAZIL: IN VITRO TOXICOLOGY TESTING SERVICES MARKET, BY END USER,
2024–2031 (USD MILLION) 485
TABLE 792 MEXICO: IN VITRO TOXICOLOGY TESTING MARKET, BY OFFERING,
2024–2031 (USD MILLION) 486
TABLE 793 MEXICO: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 487
TABLE 794 MEXICO: IN VITRO TOXICOLOGY TESTING REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 487
TABLE 795 MEXICO: IN VITRO TOXICOLOGY TESTING ASSAY KITS MARKET, BY TYPE,
2024–2031 (USD MILLION) 487
TABLE 796 MEXICO: IN VITRO TOXICOLOGY TESTING EQUIPMENT MARKET, BY TYPE,
2024–2031 (USD MILLION) 488
TABLE 797 MEXICO: DETECTION, IMAGING, AND ANALYTICAL SYSTEMS MARKET, BY TYPE, 2024–2031 (USD MILLION) 488
TABLE 798 MEXICO: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY TOXICITY ENDPOINT & TEST, 2024–2031 (USD MILLION) 488
TABLE 799 MEXICO: ORGAN TOXICITY TESTING MARKET, BY TYPE, 2024–2031 (USD MILLION) 489
TABLE 800 MEXICO: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 489
TABLE 801 MEXICO: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY METHOD,
2024–2031 (USD MILLION) 490
TABLE 802 MEXICO: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION) 490
TABLE 803 MEXICO: IN VITRO TOXICOLOGY TESTING SERVICES MARKET, BY TYPE,
2024–2031 (USD MILLION) 491
TABLE 804 MEXICO: TOXICOLOGY TESTING SERVICES MARKET, BY TYPE,
2024–2031 (USD MILLION) 491
TABLE 805 MEXICO: IN VITRO TOXICOLOGY TESTING SERVICES MARKET, BY METHOD,
2024–2031 (USD MILLION) 492
TABLE 806 MEXICO: IN VITRO TOXICOLOGY TESTING SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 492
TABLE 807 REST OF LATIN AMERICA: IN VITRO TOXICOLOGY TESTING MARKET, BY OFFERING, 2024–2031 (USD MILLION) 493
TABLE 808 REST OF LATIN AMERICA: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 493
TABLE 809 REST OF LATIN AMERICA: IN VITRO TOXICOLOGY TESTING REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 494
TABLE 810 REST OF LATIN AMERICA: IN VITRO TOXICOLOGY TESTING ASSAY KITS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 494
TABLE 811 REST OF LATIN AMERICA: IN VITRO TOXICOLOGY TESTING EQUIPMENT MARKET,
BY TYPE, 2024–2031 (USD MILLION) 494
TABLE 812 REST OF LATIN AMERICA: DETECTION, IMAGING, AND ANALYTICAL SYSTEMS MARKET, BY TYPE, 2024–2031 (USD MILLION) 495
TABLE 813 REST OF LATIN AMERICA: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET,
BY TOXICITY ENDPOINT & TEST, 2024–2031 (USD MILLION) 495
TABLE 814 REST OF LATIN AMERICA: ORGAN TOXICITY TESTING MARKET, BY TYPE,
2024–2031 (USD MILLION) 496
TABLE 815 REST OF LATIN AMERICA: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET
, BY TECHNOLOGY, 2024–2031 (USD MILLION) 496
TABLE 816 REST OF LATIN AMERICA: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET,
BY METHOD, 2024–2031 (USD MILLION) 497
TABLE 817 REST OF LATIN AMERICA: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET,
BY END USER, 2024–2031 (USD MILLION) 497
TABLE 818 REST OF LATIN AMERICA: IN VITRO TOXICOLOGY TESTING SERVICES MARKET,
BY TYPE, 2024–2031 (USD MILLION) 498
TABLE 819 REST OF LATIN AMERICA: TOXICOLOGY TESTING SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 498
TABLE 820 REST OF LATIN AMERICA: IN VITRO TOXICOLOGY TESTING SERVICES MARKET,
BY METHOD, 2024–2031 (USD MILLION) 499
TABLE 821 REST OF LATIN AMERICA: IN VITRO TOXICOLOGY TESTING SERVICES MARKET,
BY END USER, 2024–2031 (USD MILLION) 499
TABLE 822 MIDDLE EAST: IN VITRO TOXICOLOGY TESTING MARKET, BY REGION,
2024–2031 (USD MILLION) 500
TABLE 823 MIDDLE EAST: IN VITRO TOXICOLOGY TESTING MARKET, BY OFFERING,
2024–2031 (USD MILLION) 501
TABLE 824 MIDDLE EAST: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 501
TABLE 825 MIDDLE EAST: IN VITRO TOXICOLOGY TESTING REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 501
TABLE 826 MIDDLE EAST: IN VITRO TOXICOLOGY TESTING ASSAY KITS MARKET, BY TYPE, 2024–2031 (USD MILLION) 502
TABLE 827 MIDDLE EAST: IN VITRO TOXICOLOGY TESTING EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 502
TABLE 828 MIDDLE EAST: DETECTION, IMAGING, AND ANALYTICAL SYSTEMS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 502
TABLE 829 MIDDLE EAST: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY TOXICITY ENDPOINT & TEST, 2024–2031 (USD MILLION) 503
TABLE 830 MIDDLE EAST: ORGAN TOXICITY TESTING MARKET, BY TYPE,
2024–2031 (USD MILLION) 503
TABLE 831 MIDDLE EAST: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET,
BY TECHNOLOGY, 2024–2031 (USD MILLION) 504
TABLE 832 MIDDLE EAST: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY METHOD, 2024–2031 (USD MILLION) 504
TABLE 833 MIDDLE EAST: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION) 505
TABLE 834 MIDDLE EAST: IN VITRO TOXICOLOGY TESTING SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 505
TABLE 835 MIDDLE EAST: TOXICOLOGY TESTING SERVICES MARKET, BY TYPE,
2024–2031 (USD MILLION) 506
TABLE 836 MIDDLE EAST: IN VITRO TOXICOLOGY TESTING SERVICES MARKET, BY METHOD, 2024–2031 (USD MILLION) 506
TABLE 837 MIDDLE EAST: IN VITRO TOXICOLOGY TESTING SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 507
TABLE 838 GCC COUNTRIES: IN VITRO TOXICOLOGY TESTING MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 508
TABLE 839 GCC COUNTRIES: IN VITRO TOXICOLOGY TESTING MARKET, BY OFFERING,
2024–2031 (USD MILLION) 508
TABLE 840 GCC COUNTRIES: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 508
TABLE 841 GCC COUNTRIES: IN VITRO TOXICOLOGY TESTING REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 509
TABLE 842 GCC COUNTRIES: IN VITRO TOXICOLOGY TESTING ASSAY KITS MARKET, BY TYPE, 2024–2031 (USD MILLION) 509
TABLE 843 GCC COUNTRIES: IN VITRO TOXICOLOGY TESTING EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 509
TABLE 844 GCC COUNTRIES: DETECTION, IMAGING, AND ANALYTICAL SYSTEMS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 510
TABLE 845 GCC COUNTRIES: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET,
BY TOXICITY ENDPOINT & TEST, 2024–2031 (USD MILLION) 510
TABLE 846 GCC COUNTRIES: ORGAN TOXICITY TESTING MARKET, BY TYPE,
2024–2031 (USD MILLION) 511
TABLE 847 GCC COUNTRIES: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET,
BY TECHNOLOGY, 2024–2031 (USD MILLION) 511
TABLE 848 GCC COUNTRIES: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET,
BY METHOD, 2024–2031 (USD MILLION) 512
TABLE 849 GCC COUNTRIES: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET,
BY END USER, 2024–2031 (USD MILLION) 512
TABLE 850 GCC COUNTRIES: IN VITRO TOXICOLOGY TESTING SERVICES MARKET,
BY TYPE, 2024–2031 (USD MILLION) 513
TABLE 851 GCC COUNTRIES: TOXICOLOGY TESTING SERVICES MARKET, BY TYPE,
2024–2031 (USD MILLION) 513
TABLE 852 GCC COUNTRIES: IN VITRO TOXICOLOGY TESTING SERVICES MARKET, BY METHOD, 2024–2031 (USD MILLION) 514
TABLE 853 GCC COUNTRIES: IN VITRO TOXICOLOGY TESTING SERVICES MARKET,
BY END USER, 2024–2031 (USD MILLION) 514
TABLE 854 SAUDI ARABIA: IN VITRO TOXICOLOGY TESTING MARKET, BY OFFERING,
2024–2031 (USD MILLION) 515
TABLE 855 SAUDI ARABIA: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 516
TABLE 856 SAUDI ARABIA: IN VITRO TOXICOLOGY TESTING REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 516
TABLE 857 SAUDI ARABIA: IN VITRO TOXICOLOGY TESTING ASSAY KITS MARKET, BY TYPE, 2024–2031 (USD MILLION) 516
TABLE 858 SAUDI ARABIA: IN VITRO TOXICOLOGY TESTING EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 517
TABLE 859 SAUDI ARABIA: DETECTION, IMAGING, AND ANALYTICAL SYSTEMS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 517
TABLE 860 SAUDI ARABIA: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY TOXICITY ENDPOINT & TEST, 2024–2031 (USD MILLION) 517
TABLE 861 SAUDI ARABIA: ORGAN TOXICITY TESTING MARKET, BY TYPE,
2024–2031 (USD MILLION) 518
TABLE 862 SAUDI ARABIA: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 518
TABLE 863 SAUDI ARABIA: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY METHOD, 2024–2031 (USD MILLION) 519
TABLE 864 SAUDI ARABIA: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION) 519
TABLE 865 SAUDI ARABIA: IN VITRO TOXICOLOGY TESTING SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 520
TABLE 866 SAUDI ARABIA: TOXICOLOGY TESTING SERVICES MARKET, BY TYPE,
2024–2031 (USD MILLION) 520
TABLE 867 SAUDI ARABIA: IN VITRO TOXICOLOGY TESTING SERVICES MARKET, BY METHOD, 2024–2031 (USD MILLION) 521
TABLE 868 SAUDI ARABIA: IN VITRO TOXICOLOGY TESTING SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 521
TABLE 869 UAE: IN VITRO TOXICOLOGY TESTING MARKET, BY OFFERING,
2024–2031 (USD MILLION) 522
TABLE 870 UAE: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 523
TABLE 871 UAE: IN VITRO TOXICOLOGY TESTING REAGENTS & CONSUMABLES MARKET,
BY TYPE, 2024–2031 (USD MILLION) 523
TABLE 872 UAE: IN VITRO TOXICOLOGY TESTING ASSAY KITS MARKET, BY TYPE,
2024–2031 (USD MILLION) 523
TABLE 873 UAE: IN VITRO TOXICOLOGY TESTING EQUIPMENT MARKET, BY TYPE,
2024–2031 (USD MILLION) 524
TABLE 874 UAE: DETECTION, IMAGING, AND ANALYTICAL SYSTEMS MARKET, BY TYPE,
2024–2031 (USD MILLION) 524
TABLE 875 UAE: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY TOXICITY ENDPOINT & TEST, 2024–2031 (USD MILLION) 524
TABLE 876 UAE: ORGAN TOXICITY TESTING MARKET, BY TYPE, 2024–2031 (USD MILLION) 525
TABLE 877 UAE: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 525
TABLE 878 UAE: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY METHOD,
2024–2031 (USD MILLION) 526
TABLE 879 UAE: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY END USER,
2024–2031 (USD MILLION) 526
TABLE 880 UAE: IN VITRO TOXICOLOGY TESTING SERVICES MARKET, BY TYPE,
2024–2031 (USD MILLION) 527
TABLE 881 UAE: TOXICOLOGY TESTING SERVICES MARKET, BY TYPE,
2024–2031 (USD MILLION) 527
TABLE 882 UAE: IN VITRO TOXICOLOGY TESTING SERVICES MARKET, BY METHOD,
2024–2031 (USD MILLION) 528
TABLE 883 UAE: IN VITRO TOXICOLOGY TESTING SERVICES MARKET, BY END USER,
2024–2031 (USD MILLION) 528
TABLE 884 REST OF GCC COUNTRIES: IN VITRO TOXICOLOGY TESTING MARKET, BY OFFERING, 2024–2031 (USD MILLION) 529
TABLE 885 REST OF GCC COUNTRIES: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 529
TABLE 886 REST OF GCC COUNTRIES: IN VITRO TOXICOLOGY TESTING REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 530
TABLE 887 REST OF GCC COUNTRIES: IN VITRO TOXICOLOGY TESTING ASSAY KITS MARKET, BY TYPE, 2024–2031 (USD MILLION) 530
TABLE 888 REST OF GCC COUNTRIES: IN VITRO TOXICOLOGY TESTING EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 530
TABLE 889 REST OF GCC COUNTRIES: DETECTION, IMAGING, AND ANALYTICAL SYSTEMS MARKET, BY TYPE, 2024–2031 (USD MILLION) 531
TABLE 890 REST OF GCC COUNTRIES: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET
, BY TOXICITY ENDPOINT & TEST, 2024–2031 (USD MILLION) 531
TABLE 891 REST OF GCC COUNTRIES: ORGAN TOXICITY TESTING MARKET, BY TYPE,
2024–2031 (USD MILLION) 532
TABLE 892 REST OF GCC COUNTRIES: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET,
BY TECHNOLOGY, 2024–2031 (USD MILLION) 532
TABLE 893 REST OF GCC COUNTRIES: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET,
BY METHOD, 2024–2031 (USD MILLION) 533
TABLE 894 REST OF GCC COUNTRIES: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET,
BY END USER, 2024–2031 (USD MILLION) 533
TABLE 895 REST OF GCC COUNTRIES: IN VITRO TOXICOLOGY TESTING SERVICES MARKET,
BY TYPE, 2024–2031 (USD MILLION) 534
TABLE 896 REST OF GCC COUNTRIES: TOXICOLOGY TESTING SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 534
TABLE 897 REST OF GCC COUNTRIES: IN VITRO TOXICOLOGY TESTING SERVICES MARKET,
BY METHOD, 2024–2031 (USD MILLION) 535
TABLE 898 REST OF GCC COUNTRIES: IN VITRO TOXICOLOGY TESTING SERVICES MARKET,
BY END USER, 2024–2031 (USD MILLION) 535
TABLE 899 REST OF MIDDLE EAST: IN VITRO TOXICOLOGY TESTING MARKET, BY OFFERING, 2024–2031 (USD MILLION) 536
TABLE 900 REST OF MIDDLE EAST: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 536
TABLE 901 REST OF MIDDLE EAST: IN VITRO TOXICOLOGY TESTING REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 537
TABLE 902 REST OF MIDDLE EAST: IN VITRO TOXICOLOGY TESTING ASSAY KITS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 537
TABLE 903 REST OF MIDDLE EAST: IN VITRO TOXICOLOGY TESTING EQUIPMENT MARKET,
BY TYPE, 2024–2031 (USD MILLION) 537
TABLE 904 REST OF MIDDLE EAST: DETECTION, IMAGING, AND ANALYTICAL SYSTEMS MARKET, BY TYPE, 2024–2031 (USD MILLION) 538
TABLE 905 REST OF MIDDLE EAST: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET,
BY TOXICITY ENDPOINT & TEST, 2024–2031 (USD MILLION) 538
TABLE 906 REST OF MIDDLE EAST: ORGAN TOXICITY TESTING MARKET, BY TYPE,
2024–2031 (USD MILLION) 539
TABLE 907 REST OF MIDDLE EAST: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET,
BY TECHNOLOGY, 2024–2031 (USD MILLION) 539
TABLE 908 REST OF MIDDLE EAST: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET,
BY METHOD, 2024–2031 (USD MILLION) 540
TABLE 909 REST OF MIDDLE EAST: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET,
BY END USER, 2024–2031 (USD MILLION) 540
TABLE 910 REST OF MIDDLE EAST: IN VITRO TOXICOLOGY TESTING SERVICES MARKET,
BY TYPE, 2024–2031 (USD MILLION) 541
TABLE 911 REST OF MIDDLE EAST: TOXICOLOGY TESTING SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 541
TABLE 912 REST OF MIDDLE EAST: IN VITRO TOXICOLOGY TESTING SERVICES MARKET,
BY METHOD, 2024–2031 (USD MILLION) 542
TABLE 913 REST OF MIDDLE EAST: IN VITRO TOXICOLOGY TESTING SERVICES MARKET,
BY END USER, 2024–2031 (USD MILLION) 542
TABLE 914 AFRICA: IN VITRO TOXICOLOGY TESTING MARKET, BY OFFERING,
2024–2031 (USD MILLION) 543
TABLE 915 AFRICA: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 544
TABLE 916 AFRICA: IN VITRO TOXICOLOGY TESTING REAGENTS & CONSUMABLES MARKET,
BY TYPE, 2024–2031 (USD MILLION) 544
TABLE 917 AFRICA: IN VITRO TOXICOLOGY TESTING ASSAY KITS MARKET, BY TYPE,
2024–2031 (USD MILLION) 544
TABLE 918 AFRICA: IN VITRO TOXICOLOGY TESTING EQUIPMENT MARKET, BY TYPE,
2024–2031 (USD MILLION) 545
TABLE 919 AFRICA: DETECTION, IMAGING, AND ANALYTICAL SYSTEMS MARKET, BY TYPE, 2024–2031 (USD MILLION) 545
TABLE 920 AFRICA: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY TOXICITY ENDPOINT & TEST, 2024–2031 (USD MILLION) 545
TABLE 921 AFRICA: ORGAN TOXICITY TESTING MARKET, BY TYPE, 2024–2031 (USD MILLION) 546
TABLE 922 AFRICA: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 546
TABLE 923 AFRICA: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY METHOD,
2024–2031 (USD MILLION) 547
TABLE 924 AFRICA: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY END USER, 2024–2031 (USD MILLION) 547
TABLE 925 AFRICA: IN VITRO TOXICOLOGY TESTING SERVICES MARKET, BY TYPE,
2024–2031 (USD MILLION) 548
TABLE 926 AFRICA: TOXICOLOGY TESTING SERVICES MARKET, BY TYPE,
2024–2031 (USD MILLION) 548
TABLE 927 AFRICA: IN VITRO TOXICOLOGY TESTING SERVICES MARKET, BY METHOD,
2024–2031 (USD MILLION) 549
TABLE 928 AFRICA: IN VITRO TOXICOLOGY TESTING SERVICES MARKET, BY END USER,
2024–2031 (USD MILLION) 549
TABLE 929 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN IN VITRO TOXICOLOGY TESTING MARKET 550
TABLE 930 IN VITRO TOXICOLOGY TESTING MARKET: DEGREE OF COMPETITION 554
TABLE 931 IN VITRO TOXICOLOGY TESTING MARKET: REGION FOOTPRINT (2025) 558
TABLE 932 IN VITRO TOXICOLOGY TESTING MARKET: OFFERING FOOTPRINT (2025) 559
TABLE 933 IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET:
TECHNOLOGY FOOTPRINT (2025 560
TABLE 934 IN VITRO TOXICOLOGY TESTING MARKET: DETAILED LIST OF
KEY STARTUP/SME PLAYERS 563
TABLE 935 IN VITRO TOXICOLOGY TESTING MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SME PLAYERS, BY OFFERING AND REGION 564
TABLE 936 IN VITRO TOXICOLOGY TESTING MARKET: PRODUCT LAUNCHES,
JANUARY 2023–APRIL 2026 567
TABLE 937 HIGH-THROUGHPUT SCREENING MARKET: DEALS, JANUARY 2023–APRIL 2026 568
TABLE 938 HIGH-THROUGHPUT SCREENING MARKET: EXPANSIONS,
JANUARY 2023–APRIL 2026 568
TABLE 939 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 569
TABLE 940 THERMO FISHER SCIENTIFIC INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED 570
TABLE 941 THERMO FISHER SCIENTIFIC INC: PRODUCT LAUNCHES,
JANUARY 2023–APRIL 2026 574
TABLE 942 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2023–APRIL 2026 575
TABLE 943 THERMO FISHER SCIENTIFIC INC.: EXPANSIONS, JANUARY 2023–APRIL 2026 575
TABLE 944 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW 577
TABLE 945 AGILENT TECHNOLOGIES, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED 578
TABLE 946 AGILENT TECHNOLOGIES, INC.: PRODUCT LAUNCHES & ENHANCEMENTS,
JANUARY 2023–APRIL 2026 580
TABLE 947 AGILENT TECHNOLOGIES, INC.: DEALS, JANUARY 2023–APRIL 2026 581
TABLE 948 MERCK KGAA: COMPANY OVERVIEW 582
TABLE 949 MERCK KGAA: PRODUCTS/SERVICES/SOLUTIONS OFFERED 583
TABLE 950 MERCK KGAA: DEALS, JANUARY 2023–APRIL 2026 585
TABLE 951 EUROFINS SCIENTIFIC: COMPANY OVERVIEW 586
TABLE 952 EUROFINS SCIENTIFIC: PRODUCTS/SERVICES/SOLUTIONS OFFERED 587
TABLE 953 EUROFINS SCIENTIFIC: EXPANSIONS, JANUARY 2023–APRIL 2026 594
TABLE 954 CHARLES RIVER LABORATORIES: COMPANY OVERVIEW 595
TABLE 955 CHARLES RIVER LABORATORIES: PRODUCTS/SERVICES/SOLUTIONS OFFERED 596
TABLE 956 CHARLES RIVER LABORATORIES: PRODUCT LAUNCHES,
JANUARY 2023–APRIL 2026 600
TABLE 957 CHARLES RIVER LABORATORIES: DEALS, JANUARY 2023–APRIL 2026 600
TABLE 958 CHARLES RIVER LABORATORIES: OTHER DEVELOPMENTS,
JANUARY 2023–APRIL 2026 601
TABLE 959 LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY OVERVIEW 602
TABLE 960 LABORATORY CORPORATION OF AMERICA HOLDINGS: PRODUCTS/SERVICES/SOLUTIONS OFFERED 603
TABLE 961 LABORATORY CORPORATION OF AMERICA HOLDINGS: DEALS,
JANUARY 2023–APRIL 2026 606
TABLE 962 LABORATORY CORPORATION OF AMERICA HOLDINGS: EXPANSIONS,
JANUARY 2023–APRIL 2026 606
TABLE 963 LABORATORY CORPORATION OF AMERICA HOLDINGS: OTHER DEVELOPMENTS, JANUARY 2023–APRIL 2026 607
TABLE 964 SGS SA: COMPANY OVERVIEW 608
TABLE 965 SGS SA: PRODUCTS/SERVICES/SOLUTIONS OFFERED 609
TABLE 966 SGS SA: DEALS, JANUARY 2023–APRIL 2026 612
TABLE 967 SGS SA: EXPANSIONS, JANUARY 2023–APRIL 2026 612
TABLE 968 LONZA: COMPANY OVERVIEW 613
TABLE 969 LONZA: PRODUCTS/SERVICES/SOLUTIONS OFFERED 614
TABLE 970 REVVITY: COMPANY OVERVIEW 616
TABLE 971 REVVITY: PRODUCTS/SERVICES/SOLUTIONS OFFERED 617
TABLE 972 REVVITY: PRODUCT LAUNCHES, JANUARY 2023–APRIL 2026 619
TABLE 973 REVVITY: OTHER DEVELOPMENTS, JANUARY 2023–APRIL 2026 619
TABLE 974 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW 620
TABLE 975 BIO-RAD LABORATORIES, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED 621
TABLE 976 BIO-RAD LABORATORIES, INC.: PRODUCT LAUNCHES, JANUARY 2023–APRIL 2026 623
TABLE 977 BIO-RAD LABORATORIES, INC.: DEALS, JANUARY 2023–APRIL 2026 624
TABLE 978 EVOTEC SE: COMPANY OVERVIEW 625
TABLE 979 EVOTEC SE: PRODUCTS/SERVICES/SOLUTIONS OFFERED 626
TABLE 980 EVOTEC SE: DEALS, JANUARY 2023–APRIL 2026 633
TABLE 981 LABORATORY CORPORATION OF AMERICA HOLDINGS: OTHER DEVELOPMENTS, JANUARY 2023–APRIL 2026 633
TABLE 982 NOVO HOLDINGS: BUSINESS OVERVIEW 634
TABLE 983 INTERTEK GROUP PLC: BUSINESS OVERVIEW 635
TABLE 984 INOTIV: BUSINESS OVERVIEW 638
TABLE 985 PROMEGA CORPORATION: BUSINESS OVERVIEW 642
TABLE 986 PROMEGA CORPORATION: DEALS, JANUARY 2023–APRIL 2026 645
TABLE 987 BIOIVT: COMPANY OVERVIEW 646
TABLE 988 CREATIVE BIOLABS: COMPANY OVERVIEW 647
TABLE 989 MEDICILON: COMPANY OVERVIEW 648
TABLE 990 CREATIVE BIOARRAY: COMPANY OVERVIEW 649
TABLE 991 ARAGEN LIFE SCIENCES LTD.: COMPANY OVERVIEW 650
TABLE 992 ENZO BIOCHEM INC.: COMPANY OVERVIEW 652
TABLE 993 MICROBAC LABORATORIES, INC.: COMPANY OVERVIEW 655
TABLE 994 VIMTA LABS LTD.: COMPANY OVERVIEW 657
TABLE 995 PACIFIC BIOLABS, INC.: COMPANY OVERVIEW 658
TABLE 996 MB RESEARCH LABORATORIES: COMPANY OVERVIEW 659
TABLE 997 IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS 668

LIST OF FIGURES

FIGURE 1 MARKET SCENARIO 64
FIGURE 2 GLOBAL IN VITRO TOXICOLOGY TESTING MARKET, 2024–2031 65
FIGURE 3 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN IN VITRO TOXICOLOGY TESTING MARKET, 2023–2026 65
FIGURE 4 DISRUPTIONS INFLUENCING THE GROWTH OF IN VITRO TOXICOLOGY TESTING MARKET 66
FIGURE 5 HIGH-GROWTH SEGMENTS IN IN VITRO TOXICOLOGY TESTING MARKET,
2026–2031 67
FIGURE 6 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN IN VITRO TOXICOLOGY TESTING MARKET, IN TERMS OF VALUE, DURING FORECAST PERIOD 68
FIGURE 7 SHIFT TOWARDS NON-ANIMAL TOXICOLOGY TESTING METHODS TO DRIVE MARKET GROWTH 69
FIGURE 8 REAGENTS & CONSUMABLES ACCOUNTED FOR THE LARGEST SHARE OF THE IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET IN NORTH AMERICA IN 2025 70
FIGURE 9 ASIA PACIFIC IS LIKELY TO BE THE FASTEST-GROWING REGIONAL MARKET DURING THE FORECAST PERIOD 71
FIGURE 10 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO DOMINATE MARKET DURING FORECAST PERIOD 71
FIGURE 11 IN VITRO TOXICOLOGY TESTING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 72
FIGURE 12 IN VITRO TOXICOLOGY TESTING MARKET: PORTERS FIVE FORCES ANALYSIS 79
FIGURE 13 IN VITRO TOXICOLOGY TESTING MARKET: VALUE CHAIN ANALYSIS 82
FIGURE 14 IN VITRO TOXICOLOGY TESTING MARKET: ECOSYSTEM ANALYSIS 84
FIGURE 15 IN VITRO TOXICOLOGY TESTING MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 88
FIGURE 16 TOP APPLICANTS/OWNERS (COMPANIES) FOR IN VITRO TOXICOLOGY TESTING PATENTS, 2015–2025 96
FIGURE 17 IMPACT OF AI/GEN AI ON IN VITRO TOXICOLOGY TESTING MARKET 98
FIGURE 18 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY OFFERING 110
FIGURE 19 KEY BUYING CRITERIA, BY END USER 111
FIGURE 20 NORTH AMERICA: IN VITRO TOXICOLOGY TESTING MARKET SNAPSHOT 344
FIGURE 21 ASIA PACIFIC: IN VITRO TOXICOLOGY TESTING MARKET SNAPSHOT 421
FIGURE 23 IN VITRO TOXICOLOGY TESTING MARKET SHARE, BY KEY PLAYER, 2025 553
FIGURE 24 IN VITRO TOXICOLOGY TESTING MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025 556
FIGURE 25 IN VITRO TOXICOLOGY TESTING MARKET: COMPANY FOOTPRINT 557
FIGURE 26 IN VITRO TOXICOLOGY TESTING MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025 562
FIGURE 27 EV/EBITDA OF KEY VENDORS 565
FIGURE 28 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF
KEY VENDORS 565
FIGURE 29 IN VITRO TOXICITY TESTING MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS 566
FIGURE 30 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2025) 570
FIGURE 31 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2025) 578
FIGURE 32 MERCK KGAA: COMPANY SNAPSHOT (2025) 583
FIGURE 33 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2025) 587
FIGURE 34 CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT (2025) 596
FIGURE 35 LABORATORY CORPORATION OF AMERICA HOLDINGS:
COMPANY SNAPSHOT (2025) 603
FIGURE 36 SGS SA: COMPANY SNAPSHOT (2025) 609
FIGURE 37 LONZA: COMPANY SNAPSHOT (2025) 614
FIGURE 38 REVVITY: COMPANY SNAPSHOT (2025) 617
FIGURE 39 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2025) 621
FIGURE 40 EVOTEC SE: COMPANY SNAPSHOT (2025) 626
FIGURE 41 INTERTEK GROUP PLC: COMPANY SNAPSHOT (2025) 636
FIGURE 42 INOTIV: COMPANY SNAPSHOT (2025) 639
FIGURE 43 RESEARCH DESIGN 660
FIGURE 44 IN VITRO TOXICOLOGY TESTING MARKET: BREAKDOWN OF PRIMARIES 662
FIGURE 45 IN VITRO TOXICOLOGY TESTING: MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2025 663
FIGURE 46 MARKET SIZE ESTIMATION: APPROACH 1 (REVENUE SHARE ANALYSIS), 2025 664
FIGURE 47 ILLUSTRATIVE EXAMPLE OF THERMO FISHER SCIENTIFIC, INC.:
REVENUE SHARE ANALYSIS, 2025 664
FIGURE 48 IVTT MARKET: INSIGHTS FROM PRIMARIES 666
FIGURE 49 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 666
FIGURE 50 IN VITRO TOXICOLOGY TESTING MARKET: CAGR PROJECTIONS 668
FIGURE 51 IN VITRO TOXICOLOGY TESTING MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, CHALLENGES, AND OPPORTUNITIES 669
FIGURE 52 DATA TRIANGULATION METHODOLOGY 670

---

---